Azenta (AZTA) 10-Q 9 May 24 2024 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - $ / shares	6 Months Ended
	Mar. 31, 2024	May 06, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2024
Document Transition Report	false
Entity File Number	000-25434
Entity Registrant Name	AZENTA, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-3040660
Entity Address, Address Line One	200 Summit Drive
Entity Address, Address Line Two	6th Floor
Entity Address, City or Town	Burlington
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01803
City Area Code	978
Local Phone Number	262-2626
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	AZTA
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Listing, Par Value Per Share	$ 0.01
Entity Common Stock, Shares Outstanding		53,918,934
Entity Central Index Key	0000933974
Current Fiscal Year End Date	--09-30
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Amendment Flag	false

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Sep. 30, 2023
Current assets
Cash and cash equivalents	$ 353,491	$ 678,910
Short-term marketable securities	468,220	338,873
Accounts receivable, net of allowance for expected credit losses ($6,844 and $8,057, respectively)	154,668	156,535
Inventories	122,351	128,198
Derivative asset	350	13,036
Short-term restricted cash	3,089	4,650
Prepaid expenses and other current assets	87,897	98,754
Total current assets	1,190,066	1,418,956
Property, plant and equipment, net	200,905	205,744
Long-term marketable securities	143,018	111,338
Long-term deferred tax assets	925	571
Operating lease right-of-use assets	69,662	66,580
Goodwill	681,140	784,339
Intangible assets, net	267,626	294,301
Other assets	10,155	3,891
Total assets	2,563,497	2,885,720
Current liabilities
Accounts payable	37,319	35,796
Deferred revenue	38,323	34,614
Accrued warranty and retrofit costs	9,745	10,223
Accrued compensation and benefits	27,985	33,911
Accrued customer deposits	21,772	17,707
Accrued income taxes payable	10,706	7,378
Short-term operating lease liability	10,802	9,499
Accrued expenses and other current liabilities	46,347	61,800
Total current liabilities	202,999	210,928
Long-term tax accruals	377	380
Long-term deferred tax liabilities	62,267	67,301
Long-term operating lease liabilities	63,374	60,436
Other long-term liabilities	11,609	12,175
Total liabilities	340,626	351,220
Stockholders' equity
Preferred stock, $0.01 par value - 1,000,000 shares authorized, no shares issued or outstanding
Common stock, $0.01 par value - 125,000,000 shares authorized, 68,464,925 shares issued and 54,614,041 shares outstanding at March 31, 2024, 71,294,247 shares issued and 57,832,378 shares outstanding at September 30, 2023	681	713
Additional paid-in capital	999,333	1,156,160
Accumulated other comprehensive loss	(41,728)	(62,426)
Treasury stock, at cost - 13,850,884 shares at March 31, 2024 and 13,461,869 shares at September 30, 2023	(223,820)	(200,956)
Retained earnings	1,488,405	1,641,009
Total stockholders' equity	2,222,871	2,534,500
Total liabilities and stockholders' equity	$ 2,563,497	$ 2,885,720

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2024	Sep. 30, 2023
Accounts Receivable, after Allowance for Credit Loss, Current [Abstract]
Allowance for expected credit losses	$ 6,844	$ 8,057
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	125,000,000	125,000,000
Common stock, shares issued (in shares)	68,464,925	71,294,247
Common stock, shares outstanding (in shares)	54,614,041	57,832,378
Treasury Stock, Number of Shares and Restriction Disclosures [Abstract]
Treasury stock, shares (in shares)	13,850,884	13,461,869

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Revenue
Total revenue	$ 159,134	$ 148,401	$ 313,451	$ 326,767
Cost of revenue
Total cost of revenue	95,749	95,165	188,554	199,666
Gross profit	63,385	53,236	124,897	127,101
Operating expenses
Research and development	8,707	8,520	17,200	16,056
Selling, general and administrative	78,314	73,339	156,890	165,891
Impairment of goodwill and intangible assets	115,975		115,975
Contingent consideration - fair value adjustments		(17,145)		(17,145)
Restructuring charges	7,344	1,499	8,464	2,961
Total operating expenses	210,340	66,213	298,529	167,763
Operating loss	(146,955)	(12,977)	(173,632)	(40,662)
Other income
Interest income, net	9,565	10,394	19,646	21,059
Other income (expense), net	250	(2,668)	932	(1,523)
Loss before income taxes	(137,140)	(5,251)	(153,054)	(21,126)
Income tax benefit	(260)	(3,260)	(450)	(7,900)
Loss from continuing operations	(136,880)	(1,991)	(152,604)	(13,226)
Loss from discontinued operations, net of tax		(2,936)		(2,936)
Net loss	$ (136,880)	$ (4,927)	$ (152,604)	$ (16,162)
Basic net loss per share:
Loss from continuing operations (in dollars per share)	$ (2.47)	$ (0.03)	$ (2.72)	$ (0.19)
Loss from discontinued operations, net of tax (in dollars per share)		(0.04)		(0.04)
Basic net loss per share (in dollars per share)	(2.47)	(0.07)	(2.72)	(0.23)
Diluted net loss per share:
Loss from continuing operations (in dollars per share)	(2.47)	(0.03)	(2.72)	(0.19)
Loss from discontinued operations, net of tax (in dollars per share)		(0.04)		(0.04)
Diluted net loss per share (in dollars per share)	$ (2.47)	$ (0.07)	$ (2.72)	$ (0.23)
Weighted average shares used in computing net loss per share:
Basic (in shares)	55,440	69,111	56,078	70,858
Diluted (in shares)	55,440	69,111	56,078	70,858
Products
Revenue
Total revenue	$ 59,017	$ 51,917	$ 112,410	$ 137,715
Cost of revenue
Total cost of revenue	41,658	40,009	78,496	94,108
Services
Revenue
Total revenue	100,117	96,484	201,041	189,052
Cost of revenue
Total cost of revenue	$ 54,091	$ 55,156	$ 110,058	$ 105,558

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Statement of Comprehensive Income [Abstract]
Net Income (Loss)	$ (136,880)	$ (4,927)	$ (152,604)	$ (16,162)
Other comprehensive income (loss), net of tax
Net investment hedge currency translation adjustment, net of tax effects of $(1,739) and $2,837 for the three and six months ended March 31, 2024, respectively, and ($4,531) and ($24,239) for the three and six months ended March 31, 2023, respectively	5,080	(13,133)	(8,288)	(70,260)
Foreign currency translation adjustments	(20,769)	33,850	25,725	111,264
Changes in unrealized gains on marketable securities, net of tax effects of $(257) and $607 for the three and six months ended March 31, 2024, respectively, and $858 and $1,395 for the three and six months ended March 31, 2023, respectively	752	2,487	3,276	4,042
Actuarial (loss) in pension plans, net of tax effects of $(3) and $(1) during the three and six months ended March 31, 2024, respectively, and $0 during each of the three and six months ended March 31, 2023	(7)		(15)
Total other comprehensive income (loss), net of tax	(14,944)	23,204	20,698	45,046
Comprehensive income (loss)	$ (151,824)	$ 18,277	$ (131,906)	$ 28,884

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent, Parenthetical Disclosure [Abstract]
Net investment hedge currency translation adjustment, tax	$ (1,739)	$ (4,531)	$ 2,837	$ (24,239)
Changes in unrealized gains on marketable securities, tax	(257)	858	607	1,395
Actuarial loss, tax	$ (3)	$ 0	$ (1)	$ 0

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities
Net loss	$ (152,604)	$ (16,162)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	44,214	42,140
Impairment of goodwill and intangible assets	115,975
Non-cash write-offs of assets	6,966
Stock-based compensation	8,804	6,096
Contingent consideration adjustment		(17,145)
Amortization and accretion on marketable securities	(2,084)	(5,284)
Deferred income taxes	(9,456)	(20,843)
Purchase accounting impact on inventory		5,781
Loss on disposals of property, plant and equipment	260	31
Changes in operating assets and liabilities:
Accounts receivable	2,922	23,925
Inventories	7,975	(11,504)
Accounts payable	936	(5,677)
Deferred revenue	3,379	3,625
Accrued warranty and retrofit costs	(714)	622
Accrued compensation and tax withholdings	(6,153)	(21,797)
Accrued restructuring costs	1,454	820
Other assets and liabilities	12,913	(23,798)
Net cash provided by (used in) operating activities	34,787	(39,170)
Cash flows from investing activities
Purchases of property, plant and equipment	(18,746)	(21,705)
Purchases of marketable securities	(345,447)	(233,584)
Sales and maturities of marketable securities	190,504	728,171
Net Investment hedge settlement	1,476	29,313
Acquisitions, net of cash acquired		(387,665)
Net cash provided by (used in) investing activities	(172,213)	114,530
Cash flows from financing activities
Payments of finance leases	(386)	(230)
Withholding tax payments on net share settlements on equity awards		(4,906)
Share repurchases	(186,834)	(500,000)
Net cash used in financing activities	(187,220)	(505,136)
Effects of exchange rate changes on cash and cash equivalents	4,721	60,355
Net increase (decrease) in cash, cash equivalents and restricted cash	(319,925)	(369,421)
Cash, cash equivalents and restricted cash, beginning of period	684,045	1,041,296
Cash, cash equivalents and restricted cash, end of period	364,120	671,875
Supplemental disclosures:
Cash paid for income taxes, net	$ 5,008	$ 35,286

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2024	Sep. 30, 2023
Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets
Cash and cash equivalents of continuing operations	$ 353,491	$ 678,910
Short-term restricted cash	3,089	4,650
Long-term restricted cash included in other assets	7,540	485
Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows	$ 364,120	$ 684,045
Restricted Cash, Noncurrent, Statement of Financial Position	Other assets	Other assets

CONDENSED CONSOLIDATED STATEM_6

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Retained Earnings (Accumulated Deficit)	Treasury Stock	Total
Beginning Balance at Sep. 30, 2022	$ 885	$ 1,992,017	$ (83,916)	$ 1,655,356	$ (200,956)	$ 3,363,386
Beginning Balance (in shares) at Sep. 30, 2022	88,482,125
Increase (Decrease) in Stockholders' Equity
Shares issued under restricted stock and purchase plans, net of shares withheld for employee taxes		1,573			(4,629)	(3,056)
Shares issued under restricted stock and purchase plans, net of shares withheld for employee taxes (in shares)	210,711
Share repurchases					(500,000)	(500,000)
Share repurchases (in shares)	(6,090,134)
Retirement of treasury shares	$ (59)	(504,568)			504,629	2
Stock-based compensation		6,096				6,096
Net Income (Loss)				(16,162)		(16,162)
Net investment hedge currency translation adjustment, net of tax			(70,260)			(70,260)
Foreign currency translation adjustments			111,264			111,264
Changes in unrealized gains on marketable securities, net of tax			4,042			4,042
Other				(85)		(85)
Ending Balance at Mar. 31, 2023	$ 826	1,495,118	(38,870)	1,639,109	(200,956)	2,895,227
Ending Balance (in shares) at Mar. 31, 2023	82,602,702
Beginning Balance at Dec. 31, 2022	$ 824	1,489,554	(62,074)	1,644,041	(200,956)	2,871,389
Beginning Balance (in shares) at Dec. 31, 2022	82,515,917
Increase (Decrease) in Stockholders' Equity
Shares issued under restricted stock and purchase plans, net of shares withheld for employee taxes		1,573				1,573
Shares issued under restricted stock and purchase plans, net of shares withheld for employee taxes (in shares)	86,785
Retirement of treasury shares	$ 2					2
Stock-based compensation		3,991				3,991
Net Income (Loss)				(4,927)		(4,927)
Net investment hedge currency translation adjustment, net of tax			(13,133)			(13,133)
Foreign currency translation adjustments			33,850			33,850
Changes in unrealized gains on marketable securities, net of tax			2,487			2,487
Other				(5)		(5)
Ending Balance at Mar. 31, 2023	$ 826	1,495,118	(38,870)	1,639,109	(200,956)	2,895,227
Ending Balance (in shares) at Mar. 31, 2023	82,602,702
Beginning Balance at Sep. 30, 2023	$ 713	1,156,160	(62,426)	1,641,009	(200,956)	$ 2,534,500
Beginning Balance (in shares) at Sep. 30, 2023	71,294,247					57,832,378
Increase (Decrease) in Stockholders' Equity
Shares issued under restricted stock and purchase plans, net of shares withheld for employee taxes	$ 3	(3)
Shares issued under restricted stock and purchase plans, net of shares withheld for employee taxes (in shares)	217,947
Share repurchases	$ (12)				(188,515)	$ (188,527)
Share repurchases (in shares)	(3,436,284)
Retirement of treasury shares	$ (23)	(165,628)			165,651
Stock-based compensation		8,804				8,804
Net Income (Loss)				(152,604)		(152,604)
Net investment hedge currency translation adjustment, net of tax			(8,288)			(8,288)
Foreign currency translation adjustments			25,725			25,725
Changes in unrealized gains on marketable securities, net of tax			3,276			3,276
Actuarial loss on pension plans, net of tax			(15)			(15)
Ending Balance at Mar. 31, 2024	$ 681	999,333	(41,728)	1,488,405	(223,820)	$ 2,222,871
Ending Balance (in shares) at Mar. 31, 2024	68,075,910					54,614,041
Beginning Balance at Dec. 31, 2023	$ 692	1,045,427	(26,784)	1,625,285	(200,956)	$ 2,443,664
Beginning Balance (in shares) at Dec. 31, 2023	69,180,281
Increase (Decrease) in Stockholders' Equity
Shares issued under restricted stock and purchase plans, net of shares withheld for employee taxes	$ 1	(1)
Shares issued under restricted stock and purchase plans, net of shares withheld for employee taxes (in shares)	73,053
Share repurchases	$ (12)				(74,559)	(74,571)
Share repurchases (in shares)	(1,177,424)
Retirement of treasury shares		(51,695)			51,695
Stock-based compensation		5,602				5,602
Net Income (Loss)				(136,880)		(136,880)
Net investment hedge currency translation adjustment, net of tax			5,080			5,080
Foreign currency translation adjustments			(20,769)			(20,769)
Changes in unrealized gains on marketable securities, net of tax			752			752
Actuarial loss on pension plans, net of tax			(7)			(7)
Ending Balance at Mar. 31, 2024	$ 681	$ 999,333	$ (41,728)	$ 1,488,405	$ (223,820)	$ 2,222,871
Ending Balance (in shares) at Mar. 31, 2024	68,075,910					54,614,041

CONDENSED CONSOLIDATED STATEM_7

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent, Parenthetical Disclosure [Abstract]
Net investment hedge currency translation adjustment, tax	$ (1,739)	$ (4,531)	$ 2,837	$ (24,239)
Changes in unrealized gains on marketable securities, tax	$ (257)	$ 858	$ 607	$ 1,395

Nature of Operations

Nature of Operations	6 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations	1. Nature of Operations Azenta, Inc. (“Azenta”, or the “Company”) is a leading global provider of sample exploration and management solutions for the life sciences industry. The Company supports its customers from research and clinical development to commercialization with its sample management, automated storage, vaccine cold storage and transport, as well as genomic services expertise to help bring impactful therapies to market faster Organizational Structure Effective October 1, 2023, the Company realigned its organizational structure to three principal business segments: Sample Management Solutions (“SMS”), Multiomics, and B Medical Systems. The segment realignment had no impact on the Company’s consolidated financial position, results of operations, or cash flows. All segment information included in this Form 10-Q is reflective of this new structure and prior period information has been recast to conform to the Company’s current period presentation. Refer to Segment and Geographic Information

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Principles of Consolidation and Basis of Presentation The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and all entities where it has a controlling financial interest and have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). All intercompany balances and transactions have been eliminated in consolidation. The accompanying year-end balance sheet was derived from audited financial statements but does not include all disclosures required by GAAP. The unaudited interim Condensed Consolidated Financial Statements have been prepared on the same basis as the audited financial statements and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the Company’s financial position, results of operations, and cash flows for the periods presented. Certain information and disclosures normally included in the Company’s annual consolidated financial statements have been condensed or omitted and, accordingly, the accompanying financial information should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2023 filed with the U.S. Securities and Exchange Commission (“SEC”) on November 21, 2023 (the “2023 Annual Report on Form 10-K”). Use of Estimates The preparation of financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect amounts reported in the financial statements and notes thereto. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may differ from these estimates. Estimates are associated with recording accounts receivable, inventories, goodwill, intangible assets other than goodwill, long-lived assets, derivative financial instruments, deferred income taxes, warranty obligations, revenue over time, stock-based compensation expense, and other accounts. The Company assesses the estimates on an ongoing basis and records changes in estimates in the period they occur and become known. Foreign Currency Translation Certain transactions of the Company and its subsidiaries are denominated in currencies other than their functional currency. Foreign currency exchange gains (losses) generated from the settlement and remeasurement of these transactions are recognized in earnings and presented within “Other income” in the Condensed Consolidated Statements of Operations. Net foreign currency transaction and remeasurement losses were $0.4 million and $0.9 million for the three months ended March 31, 2024 and 2023, respectively. Net foreign currency transaction and remeasurement losses were $0.9 million and $0.8 million during the six months ended March 31, 2024 and 2023, respectively. Recently Issued Accounting Pronouncements In October 2023, the Financial Accounting Standard Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures In March 2024, the FASB issued ASU 2024-02, Codification Improvements-Amendments to Remove References to the Concepts Statements In March 2024, the SEC issued final rules under SEC Release No. 33-11275, The Enhancement and Standardization of Climate-Related Disclosures for Investors In 2021, the Organization of Economic Cooperation and Development (“OECD”) introduced its Pillar II Framework Model Rules (“Pillar 2”), which are designed to impose a 15% global minimum tax on the earnings of in-scope multinational corporations on a country-by-country basis. Certain aspects of Pillar 2 took effect on January 1, 2024 while other aspects go into effect on January 1, 2025. The Company is evaluating the potential impact of Pillar 2 on its business, as the countries in which it operates are enacting legislation implementing Pillar 2. Other For further information regarding the Company’s significant accounting policies, please refer to Note 2, Summary of Significant Accounting Policies

Business Combinations

Business Combinations	6 Months Ended
	Mar. 31, 2024
Business Combinations [Abstract]
Business Combinations	3. Business Combinations The Company recorded the assets acquired and liabilities assumed related to the following acquisitions at their fair values as of the acquisition date, from a market participant’s perspective. While the Company uses its best estimates and assumptions as part of the purchase price allocation process to value the assets acquired and liabilities assumed on the acquisition date, its estimates and assumptions are subject to refinement. Fair value estimates are based on a complex series of judgments about future events and uncertainties and rely heavily on estimates and assumptions. The judgments used to determine the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact the Company’s results of operations. The measurement period to finalize the fair values is within one year after the respective acquisition date. Acquisitions Completed in Fiscal Year 2023 Ziath, Ltd. On February 2, 2023, the Company acquired Ziath, Ltd. and its subsidiaries (“Ziath”). Based in Cambridge, United Kingdom, Ziath is a leading provider of 2D barcode readers for life science applications. Founded in 2005, Ziath’s innovative 2D barcode readers are a key component of the laboratory automation workflow serving pharmaceutical, biotechnology and academic customers worldwide. Ziath is expected to enhance the Company’s offerings, which support the entire lifecycle of sample management from specimen collection to sample registration, storage and processing. The acquisition was completed at a purchase price of $16.0 million, net of cash acquired. The acquired business is included in the SMS segment. The allocation of the consideration included $12.0 million of goodwill, $4.1 million of technology, $1.1 million of deferred tax liability, $0.6 million of customer relationships, $0.3 million of trademarks, and several other assets and liabilities. The weighted average life of completed technology is 10 years, customer relationships is 13 years, and trademarks is 13 years. The goodwill represents the Company’s ability to provide differentiated technology enabling high throughput scanning of varied formats of consumables. The goodwill is not expected to be deductible for income tax purposes. The Company did not present pro forma financial information for its consolidated results of operations for the acquisition because such results are immaterial. B Medical Systems S.á r.l. On October 3, 2022, the Company acquired B Medical Systems S.á r.l. and its subsidiaries ("B Medical") for a purchase price of $432.2 million. B Medical is a market leader in temperature-controlled storage and transportation solutions that enables the delivery of life-saving treatments to more than 150 countries worldwide. The consideration paid for B Medical was allocated to the assets acquired and liabilities assumed based on their fair values at the acquisitions date. The Company finalized purchase accounting for B Medical in the fourth quarter of fiscal year 2023 and there have been no adjustments to the purchase price allocation disclosed in Note 3, Business Combinations In performing the purchase price allocation, the Company considered, among other factors, the intended future use of acquired assets, and historical financial performance and estimates of future performance of B Medical’s business. As part of the purchase price allocations, the Company determined the identifiable intangible assets were completed technology value, trademarks, customer relationships and backlog. The fair value of the intangible assets was estimated using the income approach, specifically the multi-period excess earnings method, and the cash flow projections were discounted using a rate of 13%. The cash flows were based on estimates used to price the transaction, and the discount rate applied was benchmarked to the implied rate of return from the transaction and the weighted average cost of capital. The weighted average life of completed technology is 10 years, customer relationships is 16 years, trademarks is five years and backlog is one year. The intangible assets acquired are amortized over their respective weighted average life using methods that approximate the pattern in which the economic benefits are expected to be realized. The calculation of the excess of the purchase price over the estimated fair value of the tangible net assets and intangible assets acquired was recorded to goodwill. The goodwill recorded in connection with the transaction was largely based on the potential expansion of the Company's cold chain capabilities by adding differentiated solutions for reliable and traceable transport of temperature-controlled specimens. The goodwill is not deductible for income tax purposes. The acquired intangible assets and goodwill are subject to review for impairment if indicators of impairment develop and otherwise at least annually. See Note 6, Goodwill and Intangible Assets

Marketable Securities

Marketable Securities	6 Months Ended
	Mar. 31, 2024
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	4. Marketable Securities The Company had sales and maturities of marketable securities of $80.2 million and $121.0 million in the three months ended March 31, 2024 and 2023, respectively. The Company had sales and maturities of marketable securities of $190.5 million and $728.2 million in the six months ended March 31, 2024 and 2023, respectively. There were insignificant realized gains or losses in each of the three and six months ended March 31, 2024 and 2023 on the sale and maturity of marketable securities. The following is a summary of the amortized cost and the fair value, including accrued interest receivable as well as unrealized gains (losses) on the short-term and long-term marketable securities as of March 31, 2024 and September 30, 2023 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gross Gross ​ ​ ​ Amortized ​ Unrealized ​ Unrealized ​ ​ ​ ​ Cost ​ Losses ​ Gains ​ Fair Value March 31, 2024: ​ ​ ​ ​ U.S. Treasury securities and obligations of U.S. government agencies $ 433,188 ​ $ (902) ​ $ 8 $ 432,294 Bank certificates of deposit ​ ​ 7,870 ​ ​ (68) ​ ​ — ​ ​ 7,802 Corporate securities ​ ​ 171,648 ​ ​ (1,515) ​ ​ 3 ​ ​ 170,136 Municipal securities ​ 1,006 ​ ​ — ​ ​ — ​ 1,006 ​ ​ $ 613,712 ​ $ (2,485) ​ $ 11 ​ $ 611,238 September 30, 2023: ​ ​ ​ ​ ​ U.S. Treasury securities and obligations of U.S. government agencies ​ $ 227,804 $ (2,573) $ — ​ $ 225,231 Bank certificates of deposit ​ ​ 8,122 ​ ​ (170) ​ ​ — ​ ​ 7,952 Corporate securities ​ ​ 221,155 ​ ​ (4,127) ​ ​ — ​ ​ 217,028 ​ ​ $ 457,081 ​ $ (6,870) ​ $ — ​ $ 450,211 ​ The fair values of the marketable securities by contractual maturities as of March 31, 2024 were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortized ​ ​ ​ ​ ​ Cost ​ ​ Fair Value Due in one year or less ​ $ 470,012 ​ $ 468,220 Due after one year through five years ​ 140,222 ​ 139,540 Due after five years through ten years ​ ​ — ​ ​ — Due after ten years ​ 3,478 ​ 3,478 Total marketable securities ​ $ 613,712 ​ $ 611,238 ​ Expected maturities could differ from contractual maturities because the security issuers may have the right to prepay obligations without prepayment penalties. Unrealized losses from fixed-income securities are primarily attributable to changes in interest rates. The Company does not believe any unrealized losses represent impairments based on its evaluation of the available evidence.

Derivative Instruments

Derivative Instruments	6 Months Ended
	Mar. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments	5. Derivative Instruments The Company has transactions and balances denominated in currencies other than the functional currency of the transacting entity. Most of these transactions carry foreign exchange risk in Germany, the United Kingdom and China. The Company enters into foreign exchange contracts to reduce its exposure to currency fluctuations. Net gains and losses related to foreign exchange contracts are recorded as a component of “Other income” in the Condensed Consolidated Statements of Operations and are as follows for the three and six months ended March 31, 2024 and 2023 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ March 31, ​ March 31, ​ 2024 2023 2024 2023 Realized losses on derivatives not designated as hedging instruments ​ $ (548) ​ $ (533) ​ $ (1,787) ​ $ (2,112) ​ The notional amounts of the Company’s derivative instruments as of March 31, 2024 and September 30, 2023 were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, September 30, ​ ​ Hedge Designation ​ ​ 2024 ​ ​ 2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ Cross-currency swap ​ Net Investment Hedge ​ $ 75,978 ​ $ 436,360 Foreign exchange contracts ​ Undesignated ​ ​ 73,415 ​ ​ 184,800 ​ The fair values of the foreign exchange contracts are recorded in the Condensed Consolidated Balance Sheets as “Prepaid expenses and other current assets” and “Accrued expenses and other current liabilities”. Foreign exchange contract assets and liabilities are measured and reported at fair value based on observable market inputs and classified within Level 2 of the fair value hierarchy described further in Note 2, Summary of Significant Accounting Policies Fair Value Measurements Hedging Activities On February 1, 2022, the Company entered into a cross-currency swap agreement to hedge the variability of exchange rate impacts between the U. S. dollar and the Euro. Under the terms of the cross-currency swap agreement, the Company notionally exchanged $1.0 billion for €915.0 million at a weighted average interest rate of 1.20% . The designated notional amount was $960.0 million, and the actual interest rate was 1.28% . The 1.28% rate was in the range of the market value for February 1, 2022 and was the true interest rate on the notional amount. The Company designated the cross-currency swap as a hedge of net investments against one of its Euro denominated subsidiaries requiring an exchange of the notional amounts at maturity. At the maturity of the cross currency-swap on February 1, 2023, the Company delivered a notional amount of €852.0 million and received a notional amount of $960.0 million at a Euro to U.S. dollar exchange rate of 1.13 , which included a gain of $29.3 million. On February 1, 2023, the Company entered into a cross-currency swap agreement to hedge the variability of exchange rate impacts between the U.S. dollar and the Euro. Under the terms of the cross-currency swap agreement, the Company notionally exchanged $436.0 million for €400.0 million at a weighted average interest rate of 1.66%. The Company designated the cross-currency swap as a hedge of net investments against one of its Euro denominated subsidiaries, which requires an exchange of the notional amounts at maturity on February 1, 2024. At the maturity of the cross currency-swap on February 1, 2024, the Company delivered a notional amount of €400 million and received a notional amount of $436.0 million at a Euro to U.S. dollar exchange rate of 1.09, which included a gain of $1.4 million. On February 1, 2024, the Company entered into another cross-currency swap agreement to hedge the variability of exchange rate impacts between the U.S. dollar and the Euro. Under the terms of the cross-currency swap agreement, the Company notionally exchanged $76.0 million for €70.0 million at a weighted average interest rate of 1.44%. The Company designated the cross-currency swap as a hedge of net investments against one of its Euro denominated subsidiaries, which requires an exchange of the notional amounts at maturity on February 3, 2025. The cross-currency swaps were recorded as a derivative asset as of March 31, 2024 and September 30, 2023 in the Condensed Consolidated Balance Sheets. The cross-currency swap is marked to market at each reporting period, representing the fair value of the cross-currency swap, any changes in fair value are recognized as a component of “Accumulated other comprehensive loss” in the Condensed Consolidated Balance Sheets. The cross-currency swap is classified within Level 2 of the fair value hierarchy, described in Note 2, Summary of Significant Accounting Policies Fair Value Measurements Interest earned on the cross-currency swap is recorded within “Interest income, net” in the Condensed Consolidated Statements of Operations. For the three months ended March 31, 2024 and 2023, the Company recorded interest income of $1.3 million and $2.2 million, respectively, on these instruments. For the six months ended March 31, 2024 and 2023, the Company recorded interest income of $3.1 million and $5.3 million, respectively, on these instruments.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	6 Months Ended
	Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	6. Goodwill and Intangible Assets The Company conducts an impairment assessment annually, or more frequently if impairment indicators are present. Changes to the Company’s operating segments effective October 1, 2023 resulted in a change to the Company’s reporting units, which are aligned to the Company’s operating and reportable segments (as further described in Note 15, Segment and Geographic Information As a result of this segment realignment, the Company allocated goodwill to the reporting units existing under the new organizational structure on a relative fair value basis as of October 1, 2023. The Company estimated the fair values of the affected businesses based upon the present value of their anticipated future cash flows. The Company’s determination of fair value involved judgment and the use of significant estimates and assumptions, as described in the notes to the audited consolidated financial statements included in the section titled “Financial Statements and Supplementary Data” in Part II, Item 8 of the 2023 Annual Report on Form 10-K and in the “Critical Accounting Policies and Estimates” included in the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part II, Item 7 of the 2023 Annual Report on Form 10-K. In conjunction with the goodwill allocation described above, the Company tested its reporting units for potential impairment immediately before and after the segment realignment and concluded that the estimated fair value of each reporting unit exceeded its respective carrying value. As of October 1, 2023, the fair value of the B Medical Systems reporting unit exceeded its carrying value by approximately 5 percent. ​ During the second quarter of fiscal year 2024, as part of the Company’s routine long-term planning process, the Company assessed several events and circumstances that could affect the significant inputs used to determine the fair value of its reporting units, including updates to forecasted cash flows, the impact of the Company’s planned transformation initiatives and the overall change in the economic climate since its last impairment assessment in October 2023. The Company concluded it was more likely than not the fair value of the Company’s B Medical Systems segment was less than its carrying amount resulting from the reduction in the Company’s anticipated revenue growth rates for the current and subsequent years as compared to prior projections. As a result, the Company completed a quantitative goodwill impairment test for its reporting units in accordance with ASC 350, Intangibles – Goodwill ​ For the quantitative goodwill impairment analyses performed, the Company compared the estimated fair values of each of its reporting units to their respective carrying amounts. The estimated fair values of each of the reporting units were derived using the income approach, specifically the Discounted Cash Flow (“DCF”) method. The DCF models used in the analysis reflected the Company’s assumptions regarding revenue growth rates, projected gross profit margins, risk-adjusted discount rates, terminal period growth rates, economic and market trends, and other expectations about the anticipated operating results of its reporting units. As part of the goodwill impairment test, the Company also considered its market capitalization and guideline public companies in assessing the reasonableness of the combined fair values estimated for its reporting units. Goodwill impairment is measured as the excess of a reporting unit's carrying amount over its estimated fair value, not to exceed the carrying amount of goodwill for that reporting unit. ​ The results of the Company’s quantitative goodwill impairment analyses as of March 31, 2024 indicated an impairment of goodwill within its B Medical Systems reporting unit resulting in a non-cash impairment charge of $111.3 million recorded within "Impairment of goodwill and intangible assets" in its Condensed Consolidated Statements of Operations during the three months ended March 31, 2024. The Company concluded that there was no impairment to goodwill for the SMS and Multiomics reporting units as of March 31, 2024 or April 1, 2024 (the date of the Company’s annual goodwill test). ​ In the event the financial performance of any of the reporting units does not meet management’s expectations in the future, the Company experiences a prolonged macroeconomic downturn, or there are other negative revisions to key assumptions used in the DCF method used to value the reporting units, the Company may be required to perform additional impairment analyses with respect to such reporting units and could be required to recognize additional impairment charges. ​ The following table sets forth the changes in the carrying amount of goodwill by reportable segment since October 1, 2023 (in thousands). The Company has presented the October 1, 2023 balances to be consistent with the current segment structure. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Sample Management Solutions ​ Multiomics ​ B Medical Systems ​ Total Balance - October 1, 2023 ​ $ 478,601 ​ $ 196,760 ​ $ 108,978 ​ $ 784,339 Impairment ​ ​ — ​ ​ — ​ ​ (111,317) ​ ​ (111,317) Currency translation adjustments ​ ​ 5,779 ​ ​ — ​ ​ 2,339 ​ ​ 8,118 Balance - March 31, 2024 ​ $ 484,380 ​ $ 196,760 ​ $ — ​ $ 681,140 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accumulated goodwill impairments, March 31, 2024 ​ $ — ​ $ — ​ $ (111,317) ​ $ (111,317) ​ As of March 31, 2024, prior to performing the quantitative goodwill impairment analyses, the Company performed a recoverability test of B Medical Systems long-lived assets in accordance with ASC 360-10-15, Impairment or Disposal of Long-Lived Assets ​ The components of the Company’s identifiable intangible assets as of March 31, 2024 and September 30, 2023 are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2024 ​ September 30, 2023 ​ ​ ​ ​ Accumulated ​ Net Book ​ ​ ​ Accumulated ​ Net Book ​ Cost Amortization Value Cost Amortization Value Patents ​ $ 1,226 ​ $ 1,185 ​ $ 41 ​ $ 1,226 ​ $ 1,175 ​ $ 51 Completed technology ​ 225,235 ​ 74,969 ​ 150,266 ​ 215,430 ​ 56,021 ​ 159,409 Trademarks and trade names ​ 6,763 ​ 2,250 ​ 4,513 ​ 6,630 ​ 1,445 ​ 5,185 Non-competition agreements ​ ​ — ​ ​ — ​ ​ — ​ ​ 681 ​ ​ 568 ​ ​ 113 Customer relationships ​ 285,116 ​ 172,310 ​ 112,806 ​ 290,800 ​ 161,257 ​ 129,543 Other intangibles ​ ​ 887 ​ ​ 887 ​ ​ — ​ ​ 869 ​ ​ 869 ​ ​ — Total ​ $ 519,227 ​ $ 251,601 ​ $ 267,626 ​ $ 515,636 ​ $ 221,335 ​ $ 294,301 ​ Amortization expense for intangible assets was $13.0 million and $12.4 million, respectively, for the three months ended March 31, 2024 and 2023. Amortization expense for intangible assets was $25.5 million and $24.0 million, respectively, for the six months ended March 31, 2024 and 2023. During the second quarter of fiscal year 2024, the Company discontinued its sample sourcing product offering (a product line within the SMS segment). As a result, the Company recorded a $4.7 million impairment of intangible assets related to the sample sourcing business which is included in " Impairment of goodwill and intangible assets " in the Company’s Condensed Consolidated Statements of Operations in the three months ended March 31, 2024. Estimated future amortization expense for the intangible assets for the remainder of fiscal year 2024 and the subsequent five fiscal years is as follows (in thousands): ​ ​ ​ ​ ​ Remainder of fiscal year 2024 ​ $ 25,632 2025 ​ 48,883 2026 ​ 44,424 2027 ​ 36,368 2028 ​ ​ 30,051 2029 ​ ​ 24,386

Restructuring

Restructuring	6 Months Ended
	Mar. 31, 2024
Restructuring and Related Activities [Abstract]
Restructuring	7. Restructuring 2024 Restructuring Plan In the second quarter of fiscal year 2024, the Company launched initiatives designed to optimize resources for future growth and improve efficiency across its organization. The focus of the initiatives is to improve the Company’s profitability, which includes facilities consolidation, portfolio optimization, and organization structure simplification. The Company expects to complete the activities included in these initiatives by the end of fiscal year 2026. As of May 9, 2024, the date of issuance of the financial statements for the quarterly period ended March 31, 2024, the Company has not identified restructuring actions related to these initiatives that will result in additional material charges. The Company expects to identify additional actions related to these initiatives in future periods which will be recorded when specified criteria are met, such as communication of benefit arrangements or when the costs have been incurred. The majority of the restructuring expenses associated with the initiatives described above for the three months ended March 31, 2024 are severance and related costs, operating lease related right-of-use (“ROU”) asset abandonment, and fixed assets and other asset write-offs. Of the total restructuring expenses in the three months ended March 31, 2024, $4.6 million is related to B Medical Systems segment; $1.6 million is related to SMS segment; $1.1 million is the Company’s headquarters operating lease related ROU asset abandonment and corporate related severance costs. 2023 Cost Savings Plans In the second and third quarters of fiscal year 2023, the Company announced cost savings plans designed to position the Company to meet the needs of its customers and accelerate growth of the business. The restructuring expenses associated with the 2023 cost savings plans for the three and six months ended March 31, 2023 are severance and related costs. The following table sets forth restructuring charges recognized for the three and six months ended March 31, 2024 and 2023 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ Six Months Ended March 31, ​ ​ ​ 2024 ​ ​ 2023 ​ ​ ​ 2024 ​ ​ 2023 Severance and related costs ​ $ 2,111 ​ $ 1,499 ​ ​ $ 3,231 ​ $ 2,961 Property, plant and equipment and other asset write-offs ​ ​ 3,663 ​ ​ — ​ ​ ​ 3,663 ​ ​ — ROU asset abandonment ​ ​ 901 ​ ​ — ​ ​ ​ 901 ​ ​ — Other ​ ​ 669 ​ ​ — ​ ​ ​ 669 ​ ​ — Total restructuring charges ​ $ 7,344 ​ $ 1,499 ​ ​ $ 8,464 ​ $ 2,961 ​ The following table sets forth the activity in the severance and related costs accruals for the six months ended March 31, 2024 and 2023 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended March 31, ​ ​ 2024 ​ 2023 Balance at beginning of period ​ $ 1,011 ​ $ 462 Provisions ​ ​ 3,231 ​ ​ 2,961 Payments ​ ​ (1,760) ​ ​ (2,139) Balance at end of period ​ $ 2,482 ​ $ 1,284 ​

Supplementary Balance Sheet Inf

Supplementary Balance Sheet Information	6 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Supplementary Balance Sheet Information	8. Supplementary Balance Sheet Information Inventories The following is a summary of inventories at March 31, 2024 and September 30, 2023 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, September 30, ​ 2024 2023 ​ ​ Raw materials and purchased parts $ 57,101 $ 59,861 Work-in-process ​ 10,908 ​ 11,400 Finished goods ​ 54,342 ​ 56,937 Total inventories $ 122,351 $ 128,198 ​ Reserves related to write downs of inventory to net realizable value were $4.7 million and $5.0 million, respectively, at March 31, 2024 and September 30, 2023. ​ Warranty and Retrofit Costs The following is a summary of product and warranty retrofit activity for the six months ended March 31, 2024 and 2023 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended March 31, ​ ​ ​ 2024 ​ 2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance at beginning of period ​ $ 10,223 ​ $ 2,890 ​ Adjustment for acquisitions ​ ​ — ​ ​ 2,303 ​ Accruals for warranties during the period ​ ​ 645 ​ ​ 1,529 ​ Costs incurred during the period ​ ​ (1,123) ​ ​ (1,342) ​ Balance at end of period ​ $ 9,745 ​ $ 5,380

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Mar. 31, 2024
Stockholders' Equity Note [Abstract]
Stockholders' Equity	9. Stockholders’ Equity Share Repurchases During the three months ended March 31, 2024, the Company repurchased 1.2 million shares of common stock for $73.9 million (excluding fees, commissions, and excise tax) pursuant to the 2022 share repurchase authorization. During the six months ended March 31, 2024, the Company repurchased 3.5 million shares of common stock for $186.8 million (excluding fees, commissions, and excise tax) pursuant to the 2022 share repurchase authorization. As of March 31, 2024, the Company accrued $1.7 million for excise tax related to share repurchases, which is considered an additional cost of the share repurchases and a reduction to stockholders’ equity in the Condensed Consolidated Balance Sheets. ​ Accumulated Other Comprehensive Income (Loss) ​ The following is a summary of the components of accumulated other comprehensive income (loss), net of tax for the six months ended March 31, 2024 and 2023 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Unrealized ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gains (Losses) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ on Available- ​ ​ ​ Pension ​ ​ ​ ​ ​ Currency ​ for-Sale ​ Gains (Losses) ​ Liability ​ ​ ​ ​ Translation ​ Securities ​ on Derivative asset ​ Adjustments ​ ​ ​ ​ Adjustments ​ Net of tax ​ Net of tax ​ Net of tax ​ Total Balance at September 30, 2022 ​ $ (165,694) ​ $ (10,909) ​ $ 93,020 ​ $ (333) ​ $ (83,916) Other comprehensive income (loss) before reclassifications ​ ​ 111,264 ​ ​ 4,042 ​ ​ (70,260) ​ ​ — ​ ​ 45,046 Balance at March 31, 2023 ​ $ (54,430) ​ $ (6,867) ​ $ 22,760 ​ $ (333) ​ $ (38,870) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Unrealized ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gains (Losses) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ on Available- ​ ​ ​ ​ Pension ​ ​ ​ ​ ​ Currency ​ for-Sale ​ Gains (Losses) ​ Liability ​ ​ ​ ​ ​ Translation ​ Securities ​ on Derivative asset ​ Adjustments ​ ​ ​ ​ ​ Adjustments ​ Net of tax ​ Net of tax ​ Net of tax ​ ​ Total Balance at September 30, 2023 ​ $ (88,448) ​ $ (5,135) ​ $ 31,487 ​ $ (330) ​ $ (62,426) Other comprehensive income (loss) before reclassifications ​ ​ 25,725 ​ ​ 3,276 ​ ​ (8,288) ​ ​ (61) ​ ​ 20,652 Amounts reclassified from accumulated other comprehensive income (loss) ​ ​ — ​ ​ — ​ ​ — ​ ​ 46 ​ ​ 46 Balance at March 31, 2024 ​ $ (62,723) ​ $ (1,859) ​ $ 23,199 ​ $ (345) ​ $ (41,728) ​ ​ Unrealized gains (losses) on available-for-sale marketable securities are reclassified from “Accumulated other comprehensive income (loss)” into results of operations at the time of the securities’ sale, as described in Note 2, Summary of Significant Accounting Policies

Revenue from Contracts with Cus

Revenue from Contracts with Customers	6 Months Ended
	Mar. 31, 2024
Revenue from Contract with Customer [Abstract]
Revenue from Contracts with Customers	10. Revenue from Contracts with Customers Disaggregated Revenue The Company disaggregates revenue from contracts with customers in a manner that depicts how the nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factors. The following is revenue by significant business line for the three and six months ended March 31, 2024 and 2023 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended March 31, ​ Six months ended March 31, ​ ​ 2024 ​ 2023 ​ 2024 ​ 2023 Significant Business Line ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Multiomics ​ $ 62,218 ​ $ 62,236 ​ $ 124,938 ​ $ 123,326 Core Products (1) ​ ​ 44,844 ​ ​ 43,738 ​ ​ 93,730 ​ ​ 91,576 Sample Repository Solutions ​ ​ 29,293 ​ ​ 27,305 ​ ​ 59,412 ​ ​ 54,921 B Medical Systems ​ ​ 22,779 ​ ​ 15,122 ​ ​ 35,371 ​ ​ 56,944 Total revenue ​ $ 159,134 ​ $ 148,401 ​ $ 313,451 ​ $ 326,767 (1) Core Products are Automated Stores, Cryogenic Systems, Automated Sample Tube, and Consumables and Instruments. ​ Contract Balances Accounts Receivable, Net. The Company maintains an allowance for expected credit losses representing its best estimate of probable credit losses related to its existing accounts receivable. The Company determines the allowance for expected credit losses based on a number of factors, including an evaluation of customer credit worthiness, the age of the outstanding receivables, economic trends, historical experience, and other information through the payment periods. Contract Assets. Contract Liabilities. . Remaining Performance Obligations. aggregate amount of transaction consideration allocated to remaining performance obligations as of March 31, 2024 was $122.1 million. The following table summarizes when the Company expects to recognize the remaining performance obligations as revenue; the Company will recognize revenue associated with these performance obligations as transfer of control occurs (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of March 31, 2024 ​ ​ Less than 1 Year ​ Greater than 1 Year ​ Total Remaining performance obligations ​ $ 94,719 ​ $ 27,379 ​ $ 122,098

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Mar. 31, 2024
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	11. Stock-Based Compensation In accordance with the 2020 Equity Incentive Plan, the Company may issue to eligible employees options to purchase shares of the Company’s common stock, restricted stock units and other equity incentives, which vest upon the satisfaction of a performance condition and/or a service condition. In addition, the Company issues common stock to participating employees pursuant to an employee stock purchase plan, and may issue common stock awards and deferred restricted stock units to members of its board of directors in accordance with its board of director compensation program. 2020 Equity Incentive Plan The following table reflects the total stock-based compensation expense recorded during the three and six months ended March 31, 2024 and 2023 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ Six Months Ended March 31, ​ 2024 2023 2024 2023 Restricted stock units ​ $ 5,284 ​ $ 3,634 ​ $ 8,134 ​ $ 5,393 Employee stock purchase plan ​ 318 ​ 356 ​ 670 ​ 703 Total stock-based compensation expense ​ $ 5,602 ​ $ 3,990 ​ $ 8,804 ​ $ 6,096 ​ Restricted Stock Unit Activity The following table summarizes restricted stock unit activity for the six months ended March 31, 2024: ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ Average ​ ​ ​ ​ Grant-Date ​ ​ Shares ​ Fair Value Outstanding as of September 30, 2023 718,954 ​ $ 67.40 Granted 608,706 ​ $ 55.69 Vested (174,868) ​ $ 68.95 Forfeited (298,806) ​ $ 63.75 Outstanding as of March 31, 2024 853,986 ​ $ 60.01 ​ The fair value of restricted stock units vested during the three and six months ended March 31, 2024 was $2.0 million and $9.8 million, respectively. The fair value of restricted stock units vested during the three and six months ended March 31, 2023 was $2.6 million and $9.6 million, respectively. As of March 31, 2024, the future unrecognized stock-based compensation expense related to restricted stock units expected to vest is $27.2 million and is expected to be recognized over an estimated weighted average amortization period of 1.9 years. Restricted stock units granted with performance goals may also have a required service period following the achievement of all or a portion of the performance goals. The following table reflects restricted stock units granted during the six months ended March 31, 2024 and 2023: ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended March 31, ​ 2024 2023 Time-based restricted stock units ​ 220,174 ​ 356,410 Performance-based restricted stock units 388,532 215,701 Total units 608,706 572,111 ​ Time-Based Restricted Stock Unit Grants Restricted stock units granted with a required service period typically have three-year vesting schedules in which one-third Performance-Based Restricted Stock Unit Grants Performance-based restricted stock units are earned based on the achievement of performance criteria established by the Human Resources and Compensation Committee and approved by the Board of Directors. The criteria for performance-based awards are weighted and have threshold, target, and maximum performance goals. Performance-based restricted stock unit awards granted allow participants to earn 100% of restricted stock units if the Company’s performance meets or exceeds its target goal for each applicable financial metric, and up to a maximum of 200% if the Company’s performance for such metrics meets or exceeds the maximum or stretch goal. Performance below the minimum threshold for each financial metric results in award forfeiture. Performance goals are measured over a three-year period for each year’s restricted stock unit awards and at the end of the period to determine the number of restricted stock units earned, if any, by recipients who continue to meet the service requirement. Upon the third anniversary of each year’s restricted stock unit awards’ grant date, the Company’s Board of Directors approves the number of restricted stock units earned for participants who continue to meet the service requirements on the vesting date. In October 2023, the Company’s Board of Directors approved an amendment to the performance goals associated with the previously issued performance-based restricted stock units for all impacted employees, excluding members of the executive team. The performance goals, as amended, are more reflective of the current macro-economic environment and consideration toward employee retention in the competitive life sciences industry. Before the amendment, the original performance goals were not expected to be satisfied. Subsequent to the amendment, vesting became probable based on the forecasted achievement of the amended performance goals. The amendment of these restricted stock units is treated as a modification with the total compensation cost of

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	12. Fair Value Measurements See Note 2, Summary of Significant Accounting Policies ​ Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis The following tables summarize assets and liabilities measured and recorded at fair value on a recurring basis in the Condensed Consolidated Balance Sheets as of March 31, 2024 and September 30, 2023 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of March 31, 2024 Description ​ Total Fair Value ​ Level 1 ​ Level 2 ​ Level 3 Assets: ​ ​ ​ ​ Cash equivalents ​ $ 195,397 ​ $ 180,755 ​ $ 14,642 ​ $ — Available-for-sale securities ​ 611,238 ​ 225,926 ​ ​ 385,312 ​ — Foreign exchange contracts ​ 217 ​ — ​ 217 ​ — Net investment hedge ​ 350 ​ — ​ 350 ​ — Total assets ​ $ 807,202 ​ $ 406,681 ​ $ 400,521 ​ $ — Liabilities: ​ ​ ​ ​ Foreign exchange contracts ​ ​ 141 ​ ​ — ​ ​ 141 ​ ​ — Total liabilities ​ $ 141 ​ $ — ​ $ 141 ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of September 30, 2023 Description ​ Total Fair Value ​ Level 1 ​ Level 2 ​ Level 3 Assets: ​ ​ ​ ​ Cash equivalents ​ $ 525,952 ​ $ 525,952 ​ $ — ​ $ — Available-for-sale securities ​ 450,211 ​ 85,949 ​ ​ 364,262 ​ — Foreign exchange contracts ​ 44 ​ — ​ 44 ​ — Net investment hedge ​ ​ 13,036 ​ ​ — ​ 13,036 ​ — Total assets ​ $ 989,243 ​ $ 611,901 ​ $ 377,342 ​ $ — Liabilities: ​ ​ ​ ​ Foreign exchange contracts ​ $ 421 ​ $ — ​ $ 421 ​ $ — Total liabilities ​ $ 421 ​ $ — ​ $ 421 ​ $ — ​ Cash Equivalents The Company considers all highly liquid interest-earning investments with a maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents primarily consist of money market funds and U.S. government backed securities with a maturity of three months or less. They are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets. The fair values of these investments approximate their carrying values. Investments classified as Level 2 consist of debt securities that are valued using matrix pricing benchmarking because they are not actively traded and bank certificates of deposit with a maturity of three months or less. Matrix pricing is a mathematical technique used to value securities by relying on the securities’ relationship to other benchmark quoted prices. Available-For-Sale Securities Available-for-sale securities primarily consist of highly rated corporate debt securities, and U.S. government backed securities, which are classified as Level 1. Investments classified as Level 2 consist of debt securities that are valued using matrix pricing and benchmarking because they are not actively traded, and bank certificates of deposit. Foreign Exchange Contracts & Net Investment Hedge The Company’s foreign exchange contract assets and liabilities, and its net investment hedge assets are measured and reported at fair value using the market method valuation technique. The inputs to this technique utilize current foreign currency exchange forward market rates published by third-party leading financial news and data providers. These are observable data that represent the rates that the financial institution uses for contracts entered into at that date; however, they are not based on actual transactions, so they are classified as Level 2. Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis In addition to assets and liabilities that are recorded at fair value on a recurring basis, impairment indicators may subject goodwill and long-lived assets to fair value measurement on a nonrecurring basis. As described in Note 6, Goodwill and Intangible Assets, as of March 31, 2024 the Company estimated the fair value of its reporting units using a DCF model. Because the inputs to the valuation model are largely unobservable and reflect the Company’s own assumptions, goodwill and long-lived assets are classified as Level 3.

Income Taxes

Income Taxes	6 Months Ended
	Mar. 31, 2024
Income Tax Disclosure [Abstract]
Income Taxes	13. Income Taxes The Company recorded an income tax benefit of $0.3 million and $0.5 million during the three and six months ended March 31, 2024, respectively. The tax benefit was primarily driven by the pre-tax loss from operations offset by $1.7 million of charge related to a valuation allowance recorded against deferred tax assets in a foreign subsidiary during the three months ended March 31, 2024. The pre-tax benefit was further offset by $0.5 million of stock compensation shortfall expense for tax deductions that were lower than the associated book compensation expense during the six months ended March 31, 2024, and $0.7 million of expenses related to a valuation allowance on beginning of year U.S. state deferred tax assets. Additionally, the benefit was reduced by $5.7 million and $8.3 million during the three and six months ended March 31, 2024, respectively, due to a partial valuation allowance against the current year U.S. federal and state deferred tax assets. The Company’s tax rate on the loss from operations was lower than statutory rates because the Company was not providing a full tax benefit on U.S. losses due to a partial valuation allowance being recorded against U.S. federal and state deferred tax assets during the current year. The Company recorded an income tax benefit of $3.3 million and $7.9 million, respectively, during the three and six months ended March 31, 2023, respectively. The tax benefit for the three months ended March 31, 2023 was primarily driven by the pre-tax loss from continuing operations during the period. The tax benefit for the six months ended March 31, 2023 was primarily driven by the pre-tax loss from operations and a $1.4 million deferred tax benefit resulting from the extension of a tax incentive in China. The effective tax rates for the three and six months ended March 31, 2023 were substantially higher than statutory rates. The effective rates were driven higher than the statutory rates by the discrete tax benefit in China noted above and the fair value adjustment of the contingent consideration related the B Medical acquisition. The contingent consideration generated $17.1 million of pre-tax income that was not subject to income taxes. Therefore, the tax benefit was being driven by a tax loss that was significantly higher than the book loss for these periods. The effective tax rate during the six months ended March 31, 2023 without these discrete events was slightly higher than average statutory tax rates due to the jurisdictional mix of income with losses being generated in higher tax jurisdictions and income being generated in lower jurisdictions. The in the course of The Company has generated U.S. pre-tax losses in recent years but has been in an overall deferred tax liability position where future taxable temporary differences were considered sufficient to offset future deductible temporary differences. The Company expects to generate a U.S. loss during fiscal year 2024 which will result in a partial valuation allowance against U.S. federal and state deferred tax assets. In addition to the U.S. federal and state partial valuation allowance being recorded against deferred tax assets through the estimated annual effective tax rate, the Company has also recorded $0.7 million of valuation allowances against U.S. state deferred tax assets which related to beginning of year. The Company also maintains a During the three months ended March 31, 2024, the Company repatriated approximately $455.0 million in cash from its German subsidiary. The Company recorded net tax benefits in the amount of $3.2 million related to the repatriation. The benefit included $5.2 million related to deductible U.S. foreign exchange losses on the repatriation measured at the foreign exchange rate on the date of repatriation. This benefit was offset by $2.0 million of state income taxes, net of federal benefit that was recorded during fiscal year 2023. During the three months ended March 31, 2024, we reversed the $2.9 million deferred tax asset due to changes in foreign exchange rates up to the repatriation date. The impact was recorded against other comprehensive income. The Company has not provided deferred income taxes on the outside basis difference of any foreign subsidiary and maintains its general assertion of indefinite reinvestment regarding those subsidiaries and the remaining earnings of its German subsidiary as of March 31, 2024. The Company maintains liabilities for unrecognized tax benefits based on its estimates and assumptions. The Company recognizes interest related to unrecognized tax benefits as unrecognized benefits The In on those benefits will not be reduced in the next twelve months ​

Net Loss per Share

Net Loss per Share	6 Months Ended
	Mar. 31, 2024
Earnings Per Share [Abstract]
Net Loss per Share	14. Net Loss per Share The calculations of basic and diluted net loss per share and basic and diluted weighted average shares outstanding are as follows for the three and six months ended March 31, 2024 and 2023 (in thousands, except per share data): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ March 31, ​ March 31, ​ 2024 2023 2024 2023 Loss from continuing operations ​ $ (136,880) ​ $ (1,991) ​ $ (152,604) ​ $ (13,226) Loss from discontinued operations, net of tax ​ — ​ (2,936) ​ — ​ (2,936) Net loss ​ ​ (136,880) ​ ​ (4,927) ​ ​ (152,604) ​ ​ (16,162) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average common shares outstanding used in computing basic loss per share ​ 55,440 ​ 69,111 ​ 56,078 ​ 70,858 Weighted average common shares outstanding used in computing diluted loss per share ​ 55,440 ​ 69,111 ​ 56,078 ​ 70,858 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic net loss per share: ​ ​ ​ ​ Loss from continuing operations ​ $ (2.47) ​ $ (0.03) ​ $ (2.72) ​ $ (0.19) Loss from discontinued operations, net of tax ​ — ​ (0.04) ​ — ​ (0.04) Basic net loss per share ​ $ (2.47) ​ $ (0.07) ​ $ (2.72) ​ $ (0.23) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Diluted net loss per share: ​ ​ ​ ​ Loss from continuing operations ​ $ (2.47) ​ $ (0.03) ​ $ (2.72) ​ $ (0.19) Loss from discontinued operations, net of tax ​ — ​ (0.04) ​ — ​ (0.04) Diluted net loss per share ​ $ (2.47) ​ $ (0.07) ​ $ (2.72) ​ $ (0.23) ​ As a result of incurring a net loss from continuing operations for the three and six months ended March 31, 2024 and 2023, outstanding restricted stock units and shares issued by the Company under the employee stock purchase plan were excluded from the computation of diluted loss per share as their effect would be antidilutive to earnings per share for continuing operations based on the treasury stock method.

Segment and Geographic Informat

Segment and Geographic Information	6 Months Ended
	Mar. 31, 2024
Segment Reporting [Abstract]
Segment and Geographic Information	15. Segment and Geographic Information Operating segments are defined as components of an enterprise that engage in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker (“CODM”) in deciding how to allocate resources and to assess performance. The Company’s Chief Executive Officer is the Company’s CODM. Effective October 1, 2023, the Company realigned its organizational structure to three principal business segments to enhance its commercial strategy for accelerating growth and to enable additional profitability initiatives. These segments align with changes in how the Company’s CODM manages the business, allocates resources, and assesses performance. The Company’s operating and reportable segments consist of the following: ​ ● Sample Management Solutions . SMS operates as a single business unit offering end-to-end sample management products and services, including: Sample Repository Solutions and Core Products (Automated Stores, Cryogenic Systems, Automated Sample Tube, and Consumables and Instruments). ● Multiomics . The Multiomics business resources operate under a single business unit that provides genomic and other sample analysis services, including gene sequencing and gene synthesis. ● B Medical Systems . B Medical Systems business resources operate as a single business unit focused on the manufacturing and distribution of temperature-controlled storage and transportation solutions in international markets to governments, health institutions, and non-government organizations. ​ The segment realignment had no impact on the Company’s consolidated financial position, results of operations, or cash flows. All segment information is reflective of this new structure, and prior period information has been recast to conform to our current period presentation. Management considers adjusted operating loss, which excludes charges related to amortization of intangible assets, purchase accounting impact on inventory, transformation costs, restructuring charges, goodwill and intangible impairment, merger and acquisition costs and costs related to share repurchase, governance-related matters, and other unallocated corporate expenses, as the primary performance metric when evaluating the segments’ operations. The following is the summary of the financial information for the Company’s reportable segments for the three and six months ended March 31, 2024 and 2023 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ Six Months Ended March 31, ​ ​ ​ 2024 ​ 2023 ​ 2024 ​ 2023 Revenue: ​ ​ ​ ​ ​ ​ ​ Sample Management Solutions ​ ​ $ 74,137 ​ $ 71,043 ​ $ 153,142 ​ $ 146,498 Multiomics ​ ​ 62,218 ​ 62,236 ​ 124,938 ​ 123,325 B Medical Systems ​ ​ ​ 22,779 ​ ​ 15,122 ​ ​ 35,371 ​ ​ 56,944 Total revenue ​ ​ $ 159,134 ​ $ 148,401 ​ $ 313,451 ​ $ 326,767 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjusted operating loss: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Sample Management Solutions ​ ​ $ (1,567) ​ $ (6,076) ​ $ (2,423) ​ $ (9,074) Multiomics ​ ​ (2,966) ​ (3,810) ​ (6,417) ​ (7,075) B Medical Systems ​ ​ ​ (1,153) ​ ​ (3,367) ​ ​ (5,562) ​ ​ 2,936 Segment adjusted operating loss ​ ​ ​ (5,686) ​ ​ (13,254) ​ ​ (14,402) ​ ​ (13,213) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortization of completed technology ​ ​ ​ 6,373 ​ ​ 4,901 ​ ​ 12,000 ​ ​ 9,070 Purchase accounting impact on inventory ​ ​ ​ — ​ ​ 2,912 ​ ​ — ​ ​ 5,781 Amortization of intangible assets other than completed technology ​ ​ ​ 6,654 ​ ​ 7,509 ​ ​ 13,516 ​ ​ 14,882 Transformation costs (1) ​ ​ ​ 4,446 ​ ​ 10 ​ ​ 4,487 ​ ​ (55) Restructuring charges ​ ​ ​ 7,344 ​ ​ 1,499 ​ ​ 8,464 ​ ​ 2,961 Impairment of goodwill and intangible assets ​ ​ ​ 115,975 ​ ​ — ​ ​ 115,975 ​ ​ — Contingent consideration - fair value adjustments ​ ​ ​ — ​ ​ (17,145) ​ ​ — ​ ​ (17,145) Merger and acquisition costs and costs related to share repurchase (2) ​ ​ ​ 426 ​ ​ 19 ​ ​ 4,747 ​ ​ 11,857 Other unallocated corporate expenses ​ ​ ​ 51 ​ ​ 18 ​ ​ 41 ​ ​ 98 Total operating loss ​ ​ ​ (146,955) ​ ​ (12,977) ​ ​ (173,632) ​ ​ (40,662) Interest income, net ​ ​ ​ 9,565 ​ ​ 10,394 ​ ​ 19,646 ​ ​ 21,059 Other income (expense), net ​ ​ ​ 250 ​ ​ (2,668) ​ ​ 932 ​ ​ (1,523) Loss before income taxes ​ ​ $ (137,140) ​ $ (5,251) ​ $ (153,054) ​ $ (21,126) (1) Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company’s operations, processes and systems to permanently alter the Company’s operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs in the period result from actions taken as part of the Company’s 2024 transformation plan, and primarily relate to one time asset write downs associated with changes in technology, one time inventory write downs relating to restructuring actions taken in the period, and third-party consulting costs associated with process & systems re-design. (2) Includes expenses related to governance-related matters. The Company has corrected the segment adjusted operating (loss) income for the three and six months ended March 31, 2023 period as certain corporate expenses that are not part of the Company’s CODM’s review of operating segment performance were improperly included in the previously disclosed segment adjusted operating (loss) income. The previously disclosed amount of total segment adjusted operating (loss) income for the reportable segments was understated by $8.0 million and $16.5 million, respectively, for the three and six months ended March 31, 2023. The total net loss before income taxes remained unchanged in each period. ​ The following is the summary of the asset information for the Company’s reportable segments as of March 31, 2024 and September 30, 2023 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets: ​ ​ March 31, 2024 ​ September 30, 2023 ​ Sample Management Solutions ​ ​ $ 845,641 ​ $ 675,708 ​ Multiomics ​ ​ ​ 462,684 ​ ​ 534,437 ​ B Medical Systems ​ ​ ​ 248,880 ​ ​ 511,640 ​ Total assets ​ ​ $ 1,557,205 ​ $ 1,721,785 ​ ​ The following is a reconciliation of the segment assets to the corresponding amounts presented in the Condensed Consolidated Balance Sheets as of March 31, 2024 and September 30, 2023 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, September 30, ​ ​ 2024 ​ 2023 Segment assets $ 1,557,205 $ 1,721,785 Cash and cash equivalents, restricted cash and marketable securities ​ 975,358 ​ 1,134,256 Deferred tax assets ​ 925 ​ 571 Other assets ​ ​ 30,009 ​ ​ 29,108 Total assets ​ $ 2,563,497 ​ $ 2,885,720 ​ Revenue from external customers is attributed to geographic areas based on locations in which the product is shipped. Net revenue by geographic area for the three and six months ended March 31, 2024 and 2023 are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ Six Months Ended March 31, ​ 2024 ​ 2023 ​ 2024 ​ 2023 Geographic Location: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ United States ​ $ 88,398 ​ $ 86,572 ​ $ 178,990 ​ $ 174,321 Africa ​ ​ 18,942 ​ ​ 8,627 ​ ​ 26,453 ​ ​ 25,837 China ​ ​ 13,646 ​ ​ 11,979 ​ ​ 28,544 ​ ​ 25,387 United Kingdom ​ ​ 5,641 ​ ​ 5,789 ​ ​ 11,340 ​ ​ 11,202 Rest of Europe ​ ​ 23,850 ​ ​ 21,432 ​ ​ 48,682 ​ ​ 60,854 Asia Pacific/Other ​ ​ 8,657 ​ ​ 14,002 ​ ​ 19,442 ​ ​ 29,166 Total revenue ​ $ 159,134 ​ $ 148,401 ​ $ 313,451 ​ $ 326,767 ​ The Company had one individual customer that accounted for 10% or more of its consolidated revenue for the three months ended March 31, 2024 and none that accounted for 10% or more of its consolidated revenue for the three months ended March 31, 2023. This individual customer is a distributor shipping to end users in 14 countries. The Company had no individual customer that accounted for 10% or more of its consolidated revenue for the six months ended March 31, 2024 and one individual customer that accounted for 10% or more of its consolidated revenue for the six months ended March 31, 2023. This individual customer is a distributor shipping to end users in 17 countries. There were no customers that accounted for more than 10% of the Company’s accounts receivable balance as of March 31, 2024 and September 30, 2023.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	16. Commitments and Contingencies Contingencies The Company is subject to various legal proceedings, both asserted and unasserted, that arise in the ordinary course of business. The Company cannot predict the ultimate outcome of such legal proceedings or, in certain instances, provide reasonable ranges of potential losses. The Company may also have certain indemnification obligations pursuant to claims made under the definitive agreement it entered into with Edwards Vacuum LLC (a member of the Atlas Copco Group) (“Edwards”) in connection with the Company’s sale of its semiconductor cryogenics business in the fourth quarter of fiscal year 2018. In the third quarter of fiscal year 2020, Edwards asserted claims for indemnification under the definitive agreement relating to alleged breaches of representations and warranties relating to customer warranty claims and inventory (the “2020 Claim”). In addition, in January 2023, Edwards filed a lawsuit against the Company in the Supreme Court of the State of New York in the County of New York seeking indemnification from the Company under such definitive agreement for $1.0 million and other related damages, including interest and attorney’s fees, arising from a third-party claim that was included as part of their initial claims (the “2023 Claim”). In April 2023, the Company responded to and filed a counterclaim against Edwards for the 2023 Claim alleging breach of the definitive agreements by Edwards and seeking a declaratory judgment. During the third quarter of fiscal year 2023, the Company and Edwards entered into a settlement agreement related to the 2023 Claim to avoid the costs and uncertainties of potential litigation. Under the settlement agreement, the Company paid Edwards $0.8 million from one of the indemnification escrows established at closing of the sale in return for the release of the 2023 Claim and the release to the Company of any residual funds in this escrow. The Company accrued a liability of $2.5 million for the 2020 Claim and 2023 Claim of which $0.8 million was paid during the third quarter of fiscal year 2023. The 2020 Claim remains outstanding and $1.7 million remains in the balance of the accrued liability as of March 31, 2024. The Company cannot determine the probability of any losses or outcome of the 2020 Claim including the amount of any indemnifiable losses, if any, resulting from these claims. However, the Company does not believe that this claim will have a material adverse effect on its consolidated financial position or results of operations. If the resolution of the 2020 Claim results in indemnifiable losses in excess of the applicable indemnification deductibles established under the definitive agreement, Edwards would be required to seek recovery under the representation and warranty insurance Edwards obtained in connection with the closing of the sale of the semiconductor cryogenics business. Management believes that any indemnifiable losses in excess of the applicable deductibles established in the definitive agreement would be covered by such insurance. For indemnifiable claims other than those arising from breaches of representations and warranties and for indemnifiable claims arising from breaches of representations and warranties exceeding the maximum coverage of the representations and warranties insurance policy, Edwards could seek recovery of such indemnifiable losses, if any, directly from the Company. In the event of unexpected subsequent developments and given the inherent unpredictability of these matters, there can be no assurance that the Company’s assessment of any claim will reflect the ultimate outcome, and an adverse outcome in certain matters could, from time to time, have a material adverse effect on the Company’s consolidated financial position or results of operations in particular quarterly or annual periods. ​ Tariff Matter With the assistance of a third-party consultant, during the first quarter of fiscal year 2021, the Company initiated a review of the value of transactions it used for intercompany imports into the United States from its GENEWIZ business. As a result of this review and a new interpretation surrounding the valuation method used to calculate the estimated transaction value, the Company revised its estimate of the tariffs owed and paid $5.9 million to the U.S. customs authorities during fiscal year 2022, related to November 2021 and prior periods. The U.S. customs authorities are in process of reviewing the Company’s calculation of tariffs for these periods to determine if any further tariffs are owed by the Company. The Company has revised its tariff calculation methodology to align with the new interpretation provided to it by U.S. customs authorities. The estimated amount owed to the U.S. customs authorities under this revised methodology for periods after November 2021 is $3.2 million and has been accrued in the Condensed Consolidated Balance Sheets. Purchase Commitments As of March 31, 2024, the Company had non-cancellable commitments of $52.0 million, comprised of purchase orders for inventory of $47.9 million and information technology related commitments of $4.1 million.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Principles of Consolidation and Basis of Presentation	Principles of Consolidation and Basis of Presentation The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and all entities where it has a controlling financial interest and have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). All intercompany balances and transactions have been eliminated in consolidation. The accompanying year-end balance sheet was derived from audited financial statements but does not include all disclosures required by GAAP. The unaudited interim Condensed Consolidated Financial Statements have been prepared on the same basis as the audited financial statements and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the Company’s financial position, results of operations, and cash flows for the periods presented. Certain information and disclosures normally included in the Company’s annual consolidated financial statements have been condensed or omitted and, accordingly, the accompanying financial information should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2023 filed with the U.S. Securities and Exchange Commission (“SEC”) on November 21, 2023 (the “2023 Annual Report on Form 10-K”).
Use of Estimates	Use of Estimates The preparation of financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect amounts reported in the financial statements and notes thereto. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may differ from these estimates. Estimates are associated with recording accounts receivable, inventories, goodwill, intangible assets other than goodwill, long-lived assets, derivative financial instruments, deferred income taxes, warranty obligations, revenue over time, stock-based compensation expense, and other accounts. The Company assesses the estimates on an ongoing basis and records changes in estimates in the period they occur and become known.
Foreign Currency Translation	Foreign Currency Translation Certain transactions of the Company and its subsidiaries are denominated in currencies other than their functional currency. Foreign currency exchange gains (losses) generated from the settlement and remeasurement of these transactions are recognized in earnings and presented within “Other income” in the Condensed Consolidated Statements of Operations. Net foreign currency transaction and remeasurement losses were $0.4 million and $0.9 million for the three months ended March 31, 2024 and 2023, respectively. Net foreign currency transaction and remeasurement losses were $0.9 million and $0.8 million during the six months ended March 31, 2024 and 2023, respectively.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In October 2023, the Financial Accounting Standard Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures In March 2024, the FASB issued ASU 2024-02, Codification Improvements-Amendments to Remove References to the Concepts Statements In March 2024, the SEC issued final rules under SEC Release No. 33-11275, The Enhancement and Standardization of Climate-Related Disclosures for Investors In 2021, the Organization of Economic Cooperation and Development (“OECD”) introduced its Pillar II Framework Model Rules (“Pillar 2”), which are designed to impose a 15% global minimum tax on the earnings of in-scope multinational corporations on a country-by-country basis. Certain aspects of Pillar 2 took effect on January 1, 2024 while other aspects go into effect on January 1, 2025. The Company is evaluating the potential impact of Pillar 2 on its business, as the countries in which it operates are enacting legislation implementing Pillar 2.
Other	Other For further information regarding the Company’s significant accounting policies, please refer to Note 2, Summary of Significant Accounting Policies

Marketable Securities (Tables)

Marketable Securities (Tables)	6 Months Ended
	Mar. 31, 2024
Investments, Debt and Equity Securities [Abstract]
Summary of amortized cost and fair value	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gross Gross ​ ​ ​ Amortized ​ Unrealized ​ Unrealized ​ ​ ​ ​ Cost ​ Losses ​ Gains ​ Fair Value March 31, 2024: ​ ​ ​ ​ U.S. Treasury securities and obligations of U.S. government agencies $ 433,188 ​ $ (902) ​ $ 8 $ 432,294 Bank certificates of deposit ​ ​ 7,870 ​ ​ (68) ​ ​ — ​ ​ 7,802 Corporate securities ​ ​ 171,648 ​ ​ (1,515) ​ ​ 3 ​ ​ 170,136 Municipal securities ​ 1,006 ​ ​ — ​ ​ — ​ 1,006 ​ ​ $ 613,712 ​ $ (2,485) ​ $ 11 ​ $ 611,238 September 30, 2023: ​ ​ ​ ​ ​ U.S. Treasury securities and obligations of U.S. government agencies ​ $ 227,804 $ (2,573) $ — ​ $ 225,231 Bank certificates of deposit ​ ​ 8,122 ​ ​ (170) ​ ​ — ​ ​ 7,952 Corporate securities ​ ​ 221,155 ​ ​ (4,127) ​ ​ — ​ ​ 217,028 ​ ​ $ 457,081 ​ $ (6,870) ​ $ — ​ $ 450,211
Schedule of fair values of marketable securities by contractual maturities	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortized ​ ​ ​ ​ ​ Cost ​ ​ Fair Value Due in one year or less ​ $ 470,012 ​ $ 468,220 Due after one year through five years ​ 140,222 ​ 139,540 Due after five years through ten years ​ ​ — ​ ​ — Due after ten years ​ 3,478 ​ 3,478 Total marketable securities ​ $ 613,712 ​ $ 611,238

Derivative Instruments (Tables)

Derivative Instruments (Tables)	6 Months Ended
	Mar. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of realized gains (losses) on derivatives not designated as hedging instruments	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ March 31, ​ March 31, ​ 2024 2023 2024 2023 Realized losses on derivatives not designated as hedging instruments ​ $ (548) ​ $ (533) ​ $ (1,787) ​ $ (2,112)
Schedule of notional amounts of derivative instruments	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, September 30, ​ ​ Hedge Designation ​ ​ 2024 ​ ​ 2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ Cross-currency swap ​ Net Investment Hedge ​ $ 75,978 ​ $ 436,360 Foreign exchange contracts ​ Undesignated ​ ​ 73,415 ​ ​ 184,800

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Components of goodwill by business segment	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Sample Management Solutions ​ Multiomics ​ B Medical Systems ​ Total Balance - October 1, 2023 ​ $ 478,601 ​ $ 196,760 ​ $ 108,978 ​ $ 784,339 Impairment ​ ​ — ​ ​ — ​ ​ (111,317) ​ ​ (111,317) Currency translation adjustments ​ ​ 5,779 ​ ​ — ​ ​ 2,339 ​ ​ 8,118 Balance - March 31, 2024 ​ $ 484,380 ​ $ 196,760 ​ $ — ​ $ 681,140 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accumulated goodwill impairments, March 31, 2024 ​ $ — ​ $ — ​ $ (111,317) ​ $ (111,317)
Schedule of intangible assets	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2024 ​ September 30, 2023 ​ ​ ​ ​ Accumulated ​ Net Book ​ ​ ​ Accumulated ​ Net Book ​ Cost Amortization Value Cost Amortization Value Patents ​ $ 1,226 ​ $ 1,185 ​ $ 41 ​ $ 1,226 ​ $ 1,175 ​ $ 51 Completed technology ​ 225,235 ​ 74,969 ​ 150,266 ​ 215,430 ​ 56,021 ​ 159,409 Trademarks and trade names ​ 6,763 ​ 2,250 ​ 4,513 ​ 6,630 ​ 1,445 ​ 5,185 Non-competition agreements ​ ​ — ​ ​ — ​ ​ — ​ ​ 681 ​ ​ 568 ​ ​ 113 Customer relationships ​ 285,116 ​ 172,310 ​ 112,806 ​ 290,800 ​ 161,257 ​ 129,543 Other intangibles ​ ​ 887 ​ ​ 887 ​ ​ — ​ ​ 869 ​ ​ 869 ​ ​ — Total ​ $ 519,227 ​ $ 251,601 ​ $ 267,626 ​ $ 515,636 ​ $ 221,335 ​ $ 294,301
Schedule of future amortization expense	​ ​ ​ ​ ​ Remainder of fiscal year 2024 ​ $ 25,632 2025 ​ 48,883 2026 ​ 44,424 2027 ​ 36,368 2028 ​ ​ 30,051 2029 ​ ​ 24,386

Restructuring (Tables)

Restructuring (Tables)	6 Months Ended
	Mar. 31, 2024
Restructuring and Related Activities [Abstract]
Schedule of restructuring charges recognized	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ Six Months Ended March 31, ​ ​ ​ 2024 ​ ​ 2023 ​ ​ ​ 2024 ​ ​ 2023 Severance and related costs ​ $ 2,111 ​ $ 1,499 ​ ​ $ 3,231 ​ $ 2,961 Property, plant and equipment and other asset write-offs ​ ​ 3,663 ​ ​ — ​ ​ ​ 3,663 ​ ​ — ROU asset abandonment ​ ​ 901 ​ ​ — ​ ​ ​ 901 ​ ​ — Other ​ ​ 669 ​ ​ — ​ ​ ​ 669 ​ ​ — Total restructuring charges ​ $ 7,344 ​ $ 1,499 ​ ​ $ 8,464 ​ $ 2,961
Schedule of activity in the severance and related costs accruals	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended March 31, ​ ​ 2024 ​ 2023 Balance at beginning of period ​ $ 1,011 ​ $ 462 Provisions ​ ​ 3,231 ​ ​ 2,961 Payments ​ ​ (1,760) ​ ​ (2,139) Balance at end of period ​ $ 2,482 ​ $ 1,284

Supplementary Balance Sheet I_2

Supplementary Balance Sheet Information (Tables)	6 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summary of inventories	​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, September 30, ​ 2024 2023 ​ ​ Raw materials and purchased parts $ 57,101 $ 59,861 Work-in-process ​ 10,908 ​ 11,400 Finished goods ​ 54,342 ​ 56,937 Total inventories $ 122,351 $ 128,198
Summary of product warranty and retrofit activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended March 31, ​ ​ ​ 2024 ​ 2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance at beginning of period ​ $ 10,223 ​ $ 2,890 ​ Adjustment for acquisitions ​ ​ — ​ ​ 2,303 ​ Accruals for warranties during the period ​ ​ 645 ​ ​ 1,529 ​ Costs incurred during the period ​ ​ (1,123) ​ ​ (1,342) ​ Balance at end of period ​ $ 9,745 ​ $ 5,380

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Mar. 31, 2024
Stockholders' Equity Note [Abstract]
Summary of accumulated other comprehensive income (loss)	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Unrealized ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gains (Losses) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ on Available- ​ ​ ​ Pension ​ ​ ​ ​ ​ Currency ​ for-Sale ​ Gains (Losses) ​ Liability ​ ​ ​ ​ Translation ​ Securities ​ on Derivative asset ​ Adjustments ​ ​ ​ ​ Adjustments ​ Net of tax ​ Net of tax ​ Net of tax ​ Total Balance at September 30, 2022 ​ $ (165,694) ​ $ (10,909) ​ $ 93,020 ​ $ (333) ​ $ (83,916) Other comprehensive income (loss) before reclassifications ​ ​ 111,264 ​ ​ 4,042 ​ ​ (70,260) ​ ​ — ​ ​ 45,046 Balance at March 31, 2023 ​ $ (54,430) ​ $ (6,867) ​ $ 22,760 ​ $ (333) ​ $ (38,870) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Unrealized ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gains (Losses) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ on Available- ​ ​ ​ ​ Pension ​ ​ ​ ​ ​ Currency ​ for-Sale ​ Gains (Losses) ​ Liability ​ ​ ​ ​ ​ Translation ​ Securities ​ on Derivative asset ​ Adjustments ​ ​ ​ ​ ​ Adjustments ​ Net of tax ​ Net of tax ​ Net of tax ​ ​ Total Balance at September 30, 2023 ​ $ (88,448) ​ $ (5,135) ​ $ 31,487 ​ $ (330) ​ $ (62,426) Other comprehensive income (loss) before reclassifications ​ ​ 25,725 ​ ​ 3,276 ​ ​ (8,288) ​ ​ (61) ​ ​ 20,652 Amounts reclassified from accumulated other comprehensive income (loss) ​ ​ — ​ ​ — ​ ​ — ​ ​ 46 ​ ​ 46 Balance at March 31, 2024 ​ $ (62,723) ​ $ (1,859) ​ $ 23,199 ​ $ (345) ​ $ (41,728)

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	6 Months Ended
	Mar. 31, 2024
Revenue from Contract with Customer [Abstract]
Schedule of disaggregated revenue by significant business line	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended March 31, ​ Six months ended March 31, ​ ​ 2024 ​ 2023 ​ 2024 ​ 2023 Significant Business Line ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Multiomics ​ $ 62,218 ​ $ 62,236 ​ $ 124,938 ​ $ 123,326 Core Products (1) ​ ​ 44,844 ​ ​ 43,738 ​ ​ 93,730 ​ ​ 91,576 Sample Repository Solutions ​ ​ 29,293 ​ ​ 27,305 ​ ​ 59,412 ​ ​ 54,921 B Medical Systems ​ ​ 22,779 ​ ​ 15,122 ​ ​ 35,371 ​ ​ 56,944 Total revenue ​ $ 159,134 ​ $ 148,401 ​ $ 313,451 ​ $ 326,767 (1) Core Products are Automated Stores, Cryogenic Systems, Automated Sample Tube, and Consumables and Instruments.
Schedule of remaining performance obligations	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of March 31, 2024 ​ ​ Less than 1 Year ​ Greater than 1 Year ​ Total Remaining performance obligations ​ $ 94,719 ​ $ 27,379 ​ $ 122,098

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Mar. 31, 2024
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of stock-based compensation expense	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ Six Months Ended March 31, ​ 2024 2023 2024 2023 Restricted stock units ​ $ 5,284 ​ $ 3,634 ​ $ 8,134 ​ $ 5,393 Employee stock purchase plan ​ 318 ​ 356 ​ 670 ​ 703 Total stock-based compensation expense ​ $ 5,602 ​ $ 3,990 ​ $ 8,804 ​ $ 6,096
Summary of restricted stock unit activity	​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ Average ​ ​ ​ ​ Grant-Date ​ ​ Shares ​ Fair Value Outstanding as of September 30, 2023 718,954 ​ $ 67.40 Granted 608,706 ​ $ 55.69 Vested (174,868) ​ $ 68.95 Forfeited (298,806) ​ $ 63.75 Outstanding as of March 31, 2024 853,986 ​ $ 60.01 ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended March 31, ​ 2024 2023 Time-based restricted stock units ​ 220,174 ​ 356,410 Performance-based restricted stock units 388,532 215,701 Total units 608,706 572,111

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Summary of assets and liabilities measured and recorded at fair value on a recurring basis	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of March 31, 2024 Description ​ Total Fair Value ​ Level 1 ​ Level 2 ​ Level 3 Assets: ​ ​ ​ ​ Cash equivalents ​ $ 195,397 ​ $ 180,755 ​ $ 14,642 ​ $ — Available-for-sale securities ​ 611,238 ​ 225,926 ​ ​ 385,312 ​ — Foreign exchange contracts ​ 217 ​ — ​ 217 ​ — Net investment hedge ​ 350 ​ — ​ 350 ​ — Total assets ​ $ 807,202 ​ $ 406,681 ​ $ 400,521 ​ $ — Liabilities: ​ ​ ​ ​ Foreign exchange contracts ​ ​ 141 ​ ​ — ​ ​ 141 ​ ​ — Total liabilities ​ $ 141 ​ $ — ​ $ 141 ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of September 30, 2023 Description ​ Total Fair Value ​ Level 1 ​ Level 2 ​ Level 3 Assets: ​ ​ ​ ​ Cash equivalents ​ $ 525,952 ​ $ 525,952 ​ $ — ​ $ — Available-for-sale securities ​ 450,211 ​ 85,949 ​ ​ 364,262 ​ — Foreign exchange contracts ​ 44 ​ — ​ 44 ​ — Net investment hedge ​ ​ 13,036 ​ ​ — ​ 13,036 ​ — Total assets ​ $ 989,243 ​ $ 611,901 ​ $ 377,342 ​ $ — Liabilities: ​ ​ ​ ​ Foreign exchange contracts ​ $ 421 ​ $ — ​ $ 421 ​ $ — Total liabilities ​ $ 421 ​ $ — ​ $ 421 ​ $ —

Net Loss per Share (Tables)

Net Loss per Share (Tables)	6 Months Ended
	Mar. 31, 2024
Earnings Per Share [Abstract]
Schedule of the calculations of basic and diluted net income (loss) per share and basic and diluted weighted average shares outstanding	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ March 31, ​ March 31, ​ 2024 2023 2024 2023 Loss from continuing operations ​ $ (136,880) ​ $ (1,991) ​ $ (152,604) ​ $ (13,226) Loss from discontinued operations, net of tax ​ — ​ (2,936) ​ — ​ (2,936) Net loss ​ ​ (136,880) ​ ​ (4,927) ​ ​ (152,604) ​ ​ (16,162) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average common shares outstanding used in computing basic loss per share ​ 55,440 ​ 69,111 ​ 56,078 ​ 70,858 Weighted average common shares outstanding used in computing diluted loss per share ​ 55,440 ​ 69,111 ​ 56,078 ​ 70,858 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic net loss per share: ​ ​ ​ ​ Loss from continuing operations ​ $ (2.47) ​ $ (0.03) ​ $ (2.72) ​ $ (0.19) Loss from discontinued operations, net of tax ​ — ​ (0.04) ​ — ​ (0.04) Basic net loss per share ​ $ (2.47) ​ $ (0.07) ​ $ (2.72) ​ $ (0.23) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Diluted net loss per share: ​ ​ ​ ​ Loss from continuing operations ​ $ (2.47) ​ $ (0.03) ​ $ (2.72) ​ $ (0.19) Loss from discontinued operations, net of tax ​ — ​ (0.04) ​ — ​ (0.04) Diluted net loss per share ​ $ (2.47) ​ $ (0.07) ​ $ (2.72) ​ $ (0.23)

Segment and Geographic Inform_2

Segment and Geographic Information (Tables)	6 Months Ended
	Mar. 31, 2024
Segment Reporting [Abstract]
Schedule of financial information for reportable segments	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ Six Months Ended March 31, ​ ​ ​ 2024 ​ 2023 ​ 2024 ​ 2023 Revenue: ​ ​ ​ ​ ​ ​ ​ Sample Management Solutions ​ ​ $ 74,137 ​ $ 71,043 ​ $ 153,142 ​ $ 146,498 Multiomics ​ ​ 62,218 ​ 62,236 ​ 124,938 ​ 123,325 B Medical Systems ​ ​ ​ 22,779 ​ ​ 15,122 ​ ​ 35,371 ​ ​ 56,944 Total revenue ​ ​ $ 159,134 ​ $ 148,401 ​ $ 313,451 ​ $ 326,767 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjusted operating loss: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Sample Management Solutions ​ ​ $ (1,567) ​ $ (6,076) ​ $ (2,423) ​ $ (9,074) Multiomics ​ ​ (2,966) ​ (3,810) ​ (6,417) ​ (7,075) B Medical Systems ​ ​ ​ (1,153) ​ ​ (3,367) ​ ​ (5,562) ​ ​ 2,936 Segment adjusted operating loss ​ ​ ​ (5,686) ​ ​ (13,254) ​ ​ (14,402) ​ ​ (13,213) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortization of completed technology ​ ​ ​ 6,373 ​ ​ 4,901 ​ ​ 12,000 ​ ​ 9,070 Purchase accounting impact on inventory ​ ​ ​ — ​ ​ 2,912 ​ ​ — ​ ​ 5,781 Amortization of intangible assets other than completed technology ​ ​ ​ 6,654 ​ ​ 7,509 ​ ​ 13,516 ​ ​ 14,882 Transformation costs (1) ​ ​ ​ 4,446 ​ ​ 10 ​ ​ 4,487 ​ ​ (55) Restructuring charges ​ ​ ​ 7,344 ​ ​ 1,499 ​ ​ 8,464 ​ ​ 2,961 Impairment of goodwill and intangible assets ​ ​ ​ 115,975 ​ ​ — ​ ​ 115,975 ​ ​ — Contingent consideration - fair value adjustments ​ ​ ​ — ​ ​ (17,145) ​ ​ — ​ ​ (17,145) Merger and acquisition costs and costs related to share repurchase (2) ​ ​ ​ 426 ​ ​ 19 ​ ​ 4,747 ​ ​ 11,857 Other unallocated corporate expenses ​ ​ ​ 51 ​ ​ 18 ​ ​ 41 ​ ​ 98 Total operating loss ​ ​ ​ (146,955) ​ ​ (12,977) ​ ​ (173,632) ​ ​ (40,662) Interest income, net ​ ​ ​ 9,565 ​ ​ 10,394 ​ ​ 19,646 ​ ​ 21,059 Other income (expense), net ​ ​ ​ 250 ​ ​ (2,668) ​ ​ 932 ​ ​ (1,523) Loss before income taxes ​ ​ $ (137,140) ​ $ (5,251) ​ $ (153,054) ​ $ (21,126) (1) Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company’s operations, processes and systems to permanently alter the Company’s operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs in the period result from actions taken as part of the Company’s 2024 transformation plan, and primarily relate to one time asset write downs associated with changes in technology, one time inventory write downs relating to restructuring actions taken in the period, and third-party consulting costs associated with process & systems re-design. (2) Includes expenses related to governance-related matters.
Schedule of reconciliation of reportable segment assets to corresponding consolidated amounts	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets: ​ ​ March 31, 2024 ​ September 30, 2023 ​ Sample Management Solutions ​ ​ $ 845,641 ​ $ 675,708 ​ Multiomics ​ ​ ​ 462,684 ​ ​ 534,437 ​ B Medical Systems ​ ​ ​ 248,880 ​ ​ 511,640 ​ Total assets ​ ​ $ 1,557,205 ​ $ 1,721,785 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, September 30, ​ ​ 2024 ​ 2023 Segment assets $ 1,557,205 $ 1,721,785 Cash and cash equivalents, restricted cash and marketable securities ​ 975,358 ​ 1,134,256 Deferred tax assets ​ 925 ​ 571 Other assets ​ ​ 30,009 ​ ​ 29,108 Total assets ​ $ 2,563,497 ​ $ 2,885,720
Schedule of revenue from external customers attributed to geographic areas	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ Six Months Ended March 31, ​ 2024 ​ 2023 ​ 2024 ​ 2023 Geographic Location: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ United States ​ $ 88,398 ​ $ 86,572 ​ $ 178,990 ​ $ 174,321 Africa ​ ​ 18,942 ​ ​ 8,627 ​ ​ 26,453 ​ ​ 25,837 China ​ ​ 13,646 ​ ​ 11,979 ​ ​ 28,544 ​ ​ 25,387 United Kingdom ​ ​ 5,641 ​ ​ 5,789 ​ ​ 11,340 ​ ​ 11,202 Rest of Europe ​ ​ 23,850 ​ ​ 21,432 ​ ​ 48,682 ​ ​ 60,854 Asia Pacific/Other ​ ​ 8,657 ​ ​ 14,002 ​ ​ 19,442 ​ ​ 29,166 Total revenue ​ $ 159,134 ​ $ 148,401 ​ $ 313,451 ​ $ 326,767

Nature of Operations (Details)

Nature of Operations (Details) - segment	3 Months Ended		6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]
Number of reportable segments	3	3	3	3

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Gain (Loss), Foreign Currency Transaction, before Tax [Abstract]
Foreign currency transaction and remeasurement gains (losses)	$ (0.4)	$ (0.9)	$ (0.9)	$ (0.8)

Business Combinations - General

Business Combinations - General Information (Details) - country	Feb. 03, 2023	Oct. 03, 2022
Ziath Ltd and Subsidiaries
Business Acquisition, Date of Acquisition [Abstract]
Business Acquisition, Effective Date of Acquisition	Feb. 02, 2023
B Medical Systems S.a.r.l and Subsidiaries
Business Acquisition, Date of Acquisition [Abstract]
Business Acquisition, Effective Date of Acquisition		Oct. 03, 2022
B Medical Systems S.a.r.l and Subsidiaries | Minimum
Business Acquisition, Date of Acquisition [Abstract]
Number of countries in which entity operates		150

Business Combinations - Purchas

Business Combinations - Purchase Consideration (Details) - USD ($) $ in Thousands			6 Months Ended
	Feb. 03, 2023	Oct. 03, 2022	Mar. 31, 2023	Mar. 31, 2024	Sep. 30, 2023
Business Acquisition [Line Items]
Aggregate purchase price, net of cash acquired			$ 387,665
Short-term restricted cash				$ 3,089	$ 4,650
Ziath Ltd and Subsidiaries
Business Acquisition [Line Items]
Aggregate purchase price, net of cash acquired	$ 16,000
B Medical Systems S.a.r.l and Subsidiaries
Business Acquisition [Line Items]
Total purchase price		$ 432,200

Business Combinations - Amounts

Business Combinations - Amounts of Assets and Liabilities at Fair Value as of Acquisition Date (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Sep. 30, 2023	Feb. 03, 2023
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Goodwill	$ 681,140	$ 784,339
Ziath Ltd and Subsidiaries
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Deferred income taxes, net			$ 1,100
Goodwill			12,000
Ziath Ltd and Subsidiaries | Completed Technology
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Intangible assets			4,100
Ziath Ltd and Subsidiaries | Trademarks
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Intangible assets			300
Ziath Ltd and Subsidiaries | Customer Relationships
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Intangible assets			$ 600

Business Combinations - Intangi

Business Combinations - Intangible Assets Acquired (Details)	Feb. 03, 2023	Oct. 03, 2022
Ziath Ltd and Subsidiaries | Completed Technology
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted average useful life of intangible assets	10 years
Ziath Ltd and Subsidiaries | Customer Relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted average useful life of intangible assets	13 years
Ziath Ltd and Subsidiaries | Trademarks
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted average useful life of intangible assets	13 years
B Medical Systems S.a.r.l and Subsidiaries
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, valuation technique, discounted cash flow, measurement input, discount rate, percentage (as a percent)		13%
B Medical Systems S.a.r.l and Subsidiaries | Completed Technology
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted average useful life of intangible assets		10 years
B Medical Systems S.a.r.l and Subsidiaries | Customer Relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted average useful life of intangible assets		16 years
B Medical Systems S.a.r.l and Subsidiaries | Trademarks
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted average useful life of intangible assets		5 years
B Medical Systems S.a.r.l and Subsidiaries | Order or Production Backlog
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted average useful life of intangible assets		1 year

Business Combinations - Goodwil

Business Combinations - Goodwill (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Sep. 30, 2023	Feb. 03, 2023	Oct. 03, 2022
Business Combination, Goodwill [Abstract]
Goodwill	$ 681,140	$ 784,339
Ziath Ltd and Subsidiaries
Business Combination, Goodwill [Abstract]
Goodwill			$ 12,000
Goodwill deductible for tax purposes			$ 0
B Medical Systems S.a.r.l and Subsidiaries
Business Combination, Goodwill [Abstract]
Goodwill deductible for tax purposes				$ 0

Marketable Securities - General

Marketable Securities - General Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Investments, Debt and Equity Securities [Abstract]
Sales and maturities of marketable securities	$ 80,200	$ 121,000	$ 190,504	$ 728,171

Marketable Securities - Summary

Marketable Securities - Summary of Amortized Cost and Fair Value (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Sep. 30, 2023
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 613,712	$ 457,081
Gross Unrealized Losses	(2,485)	(6,870)
Gross Unrealized Gains	11
Fair Value	611,238	450,211
U.S. Treasury securities and obligations of U.S. government agencies
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	433,188	227,804
Gross Unrealized Losses	(902)	(2,573)
Gross Unrealized Gains	8
Fair Value	432,294	225,231
Bank certificates of deposits
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	7,870	8,122
Gross Unrealized Losses	(68)	(170)
Fair Value	7,802	7,952
Corporate securities
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	171,648	221,155
Gross Unrealized Losses	(1,515)	(4,127)
Gross Unrealized Gains	3
Fair Value	170,136	$ 217,028
Municipal securities
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	1,006
Fair Value	$ 1,006

Marketable Securities - Fair Va

Marketable Securities - Fair Value of Marketable Securities by Contractual Maturity (Details) $ in Thousands	Mar. 31, 2024 USD ($)
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]
Amortized cost, due in one year or less, remainder of fiscal year	$ 470,012
Amortized cost, due in one year or less	0
Amortized cost, due after one year through five years	140,222
Amortized cost, due after ten years	3,478
Amortized cost	613,712
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]
Fair value, due in one year or less, remainder of fiscal year	468,220
Fair value, due in one year or less	0
Fair value, due after one year through five years	139,540
Fair value, due after ten years	3,478
Fair value	$ 611,238

Derivative Instruments - Realiz

Derivative Instruments - Realized Gains (Losses) on Derivatives Not Designated as Hedging Instruments (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net [Abstract]
Realized gains (losses) on derivatives not designated as hedging instruments	$ (548)	$ (533)	$ (1,787)	$ (2,112)

Derivative Instruments - Notion

Derivative Instruments - Notional Amounts (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Sep. 30, 2023	Feb. 01, 2022
Foreign Exchange Contract | Not Designated as Hedging Instrument
Notional Disclosures [Abstract]
Derivative, notional amount	$ 73,415	$ 184,800
Currency Swap | Designated as Hedging Instrument
Notional Disclosures [Abstract]
Derivative, notional amount	$ 75,978	$ 436,360	$ 960,000

Derivative Instruments - Hedgin

Derivative Instruments - Hedging Activities (Details) - Currency Swap - Designated as Hedging Instrument $ in Thousands, € in Millions			3 Months Ended		6 Months Ended
	Feb. 01, 2024 USD ($) $ / €	Feb. 01, 2023 USD ($) $ / €	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	Feb. 01, 2024 EUR (€) $ / €	Sep. 30, 2023 USD ($)	Feb. 01, 2023 EUR (€) $ / €	Feb. 01, 2022 USD ($)	Feb. 01, 2022 EUR (€)
Derivative [Line Items]
Derivative, notional amount, cross-currency swap, exchanged	$ 76,000	$ 436,000								$ 1,000,000
Derivative, notional amount, cross-currency swap, received | €							€ 70		€ 400		€ 915
Derivative, notional amount			$ 75,978		$ 75,978			$ 436,360		$ 960,000
Derivative, fixed interest rate (as a percent)										1.28%	1.28%
Derivative, notional amount, cross-currency swap, maturity, deliver | €							€ 400		€ 852
Derivative, notional amount, cross-currency swap, maturity, receive	$ 436,000	$ 960,000
Derivative, forward exchange rate | $ / €	1.09	1.13					1.09		1.13
Gain on derivative	$ 1,400	$ 29,300
Interest income			$ 1,300	$ 2,200	$ 3,100	$ 5,300
Weighted Average
Derivative [Line Items]
Derivative, variable interest rate	1.44%	1.66%					1.44%		1.66%	1.20%	1.20%

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Reporting Units (Details) - USD ($) $ in Thousands	6 Months Ended
	Mar. 31, 2024	Apr. 01, 2024	Oct. 01, 2023
Goodwill [Line Items]
Goodwill impairment	$ 111,317
Accumulated goodwill impairments	111,317
B Medical Systems
Goodwill [Line Items]
Reporting unit, fair value exceeded carrying value, percentage (as a percent)			5%
Goodwill impairment	111,300
Sample Management Solutions
Goodwill [Line Items]
Accumulated goodwill impairments	0	$ 0
Multiomics
Goodwill [Line Items]
Accumulated goodwill impairments	$ 0	$ 0

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Goodwill Roll Forward (Details) $ in Thousands	6 Months Ended
	Mar. 31, 2024 USD ($)
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 784,339
Impairment	(111,317)
Currency translation adjustments	8,118
Goodwill, ending balance	681,140
Goodwill, Impaired, Accumulated Impairment Loss [Abstract]
Accumulated goodwill impairments	(111,317)
Sample Management Solutions
Goodwill [Roll Forward]
Goodwill, beginning balance	478,601
Currency translation adjustments	5,779
Goodwill, ending balance	484,380
Multiomics
Goodwill [Roll Forward]
Goodwill, beginning balance	196,760
Goodwill, ending balance	196,760
B Medical Systems
Goodwill [Roll Forward]
Goodwill, beginning balance	108,978
Impairment	(111,317)
Currency translation adjustments	2,339
Goodwill, Impaired, Accumulated Impairment Loss [Abstract]
Accumulated goodwill impairments	$ (111,317)

Goodwill And Intangible Asset_4

Goodwill And Intangible Assets - Long-Lived Assets (Details) $ in Thousands	Mar. 31, 2024 USD ($)
B Medical Systems
Segment Reporting Information [Line Items]
Impairment, long-lived asset, held-for-use, accumulated impairment loss	$ 0

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Components of Identifiable Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Sep. 30, 2023
Finite-Lived Intangible Assets [Line Items]
Cost	$ 519,227	$ 515,636
Accumulated Amortization	251,601	221,335
Net Book Value	267,626	294,301
Patents
Finite-Lived Intangible Assets [Line Items]
Cost	1,226	1,226
Accumulated Amortization	1,185	1,175
Net Book Value	41	51
Completed Technology
Finite-Lived Intangible Assets [Line Items]
Cost	225,235	215,430
Accumulated Amortization	74,969	56,021
Net Book Value	150,266	159,409
Trademarks and Trade Names
Finite-Lived Intangible Assets [Line Items]
Cost	6,763	6,630
Accumulated Amortization	2,250	1,445
Net Book Value	4,513	5,185
Non-competition agreements
Finite-Lived Intangible Assets [Line Items]
Cost		681
Accumulated Amortization		568
Net Book Value		113
Customer Relationships
Finite-Lived Intangible Assets [Line Items]
Cost	285,116	290,800
Accumulated Amortization	172,310	161,257
Net Book Value	112,806	129,543
Other Intangible Assets
Finite-Lived Intangible Assets [Line Items]
Cost	887	869
Accumulated Amortization	$ 887	$ 869

Goodwill and Intangible Asset_6

Goodwill and Intangible Assets - Amortization Expense (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 13	$ 12.4	$ 25.5	$ 24

Goodwill and Intangible Asset_7

Goodwill and Intangible Assets - Intangible Assets Impairment (Details) - Sample Management Solutions $ in Millions	3 Months Ended
	Mar. 31, 2024 USD ($)
Impairment of Intangible Assets (Excluding Goodwill) [Abstract]
Impairment of intangible assets	$ 4.7
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income	Impairment of goodwill and intangible assets

Goodwill and Intangible Asset_8

Goodwill and Intangible Assets - Estimated Future Amortization Expense of Intangible Assets (Details) $ in Thousands	Mar. 31, 2024 USD ($)
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Remainder of fiscal year 2024	$ 25,632
2025	48,883
2026	44,424
2027	36,368
2028	30,051
2029	$ 24,386

Restructuring - General Informa

Restructuring - General Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Restructuring Charges [Abstract]
Restructuring charges	$ 7,344	$ 1,499	$ 8,464	$ 2,961
ROU asset abandonment	901		$ 901
2024 Restructuring Plan
Restructuring Charges [Abstract]
ROU asset abandonment	1,100
2024 Restructuring Plan | B Medical Systems
Restructuring Charges [Abstract]
Restructuring charges	4,600
2024 Restructuring Plan | Sample Management Solutions
Restructuring Charges [Abstract]
Restructuring charges	$ 1,600

Restructuring - Total Restructu

Restructuring - Total Restructuring Charges (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Restructuring Charges [Abstract]
Severance and related costs	$ 2,111	$ 1,499	$ 3,231	$ 2,961
Property, plant and equipment and other asset write-offs	3,663		3,663
ROU asset abandonment	901		901
Other	669		669
Total restructuring charges	$ 7,344	$ 1,499	$ 8,464	$ 2,961

Restructuring - Roll Forward (D

Restructuring - Roll Forward (Details) - USD ($) $ in Thousands	6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Restructuring Reserve [Roll Forward]
Balance at beginning of period	$ 1,011	$ 462
Provisions	3,231	2,961
Payments	(1,760)	(2,139)
Balance at end of period	$ 2,482	$ 1,284

Supplementary Balance Sheet I_3

Supplementary Balance Sheet Information - Inventories - Summary of Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials and purchased parts	$ 57,101	$ 59,861
Work-in-process	10,908	11,400
Finished goods	54,342	56,937
Total inventories	$ 122,351	$ 128,198

Supplementary Balance Sheet I_4

Supplementary Balance Sheet Information - Inventories - Inventory Reserves (Details) - USD ($) $ in Millions	Mar. 31, 2024	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Reserves related to write downs of inventory to net realizable value	$ 4.7	$ 5

Supplementary Balance Sheet I_5

Supplementary Balance Sheet Information - Product Warranty and Retrofit Cost (Details) - USD ($) $ in Thousands	6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]
Balance at beginning of period	$ 10,223	$ 2,890
Adjustment for acquisitions		2,303
Accruals for warranties during the year	645	1,529
Costs incurred during the year	(1,123)	(1,342)
Balance at end of period	$ 9,745	$ 5,380

Stockholders' Equity - Share Re

Stockholders' Equity - Share Repurchase (Details) shares in Millions, $ in Millions	3 Months Ended	6 Months Ended
	Mar. 31, 2024 USD ($) shares	Mar. 31, 2024 USD ($) shares
Stockholders' Equity Note [Abstract]
Stock repurchased and retired during period, shares (in shares) | shares	1.2	3.5
Payments for repurchase of common stock, excluding fees, commissions, and excise tax	$ 73.9	$ 186.8
Exercise tax related to share repurchases	$ 1.7	$ 1.7

Stockholders' Equity - Accumula

Stockholders' Equity - Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Increase (Decrease) in Accumulated Other Comprehensive Income [Roll Forward]
Beginning Balance	$ 2,534,500	$ 3,363,386
Ending Balance	2,222,871	2,895,227
Accumulated Other Comprehensive Income (Loss)
Increase (Decrease) in Accumulated Other Comprehensive Income [Roll Forward]
Beginning Balance	(62,426)	(83,916)
Other comprehensive income (loss) before reclassifications	20,652	45,046
Amounts reclassified from accumulated other comprehensive income (loss)	46
Ending Balance	(41,728)	(38,870)
Currency Translation Adjustments
Increase (Decrease) in Accumulated Other Comprehensive Income [Roll Forward]
Beginning Balance	(88,448)	(165,694)
Other comprehensive income (loss) before reclassifications	25,725	111,264
Ending Balance	(62,723)	(54,430)
Unrealized Gains (Losses) on Available-for-Sale Securities, Net of Tax
Increase (Decrease) in Accumulated Other Comprehensive Income [Roll Forward]
Beginning Balance	(5,135)	(10,909)
Other comprehensive income (loss) before reclassifications	3,276	4,042
Ending Balance	(1,859)	(6,867)
Unrealized Gain on Derivative Asset, Net of Tax
Increase (Decrease) in Accumulated Other Comprehensive Income [Roll Forward]
Beginning Balance	31,487	93,020
Other comprehensive income (loss) before reclassifications	(8,288)	(70,260)
Ending Balance	23,199	22,760
Pension Liability Adjustments
Increase (Decrease) in Accumulated Other Comprehensive Income [Roll Forward]
Beginning Balance	(330)	(333)
Other comprehensive income (loss) before reclassifications	(61)
Amounts reclassified from accumulated other comprehensive income (loss)	46
Ending Balance	$ (345)	$ (333)

Revenue from Contracts with C_3

Revenue from Contracts with Customers - Disaggregated By Reporting Unit (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Disaggregation of Revenue [Line Items]
Total revenue	$ 159,134	$ 148,401	$ 313,451	$ 326,767
Multiomics
Disaggregation of Revenue [Line Items]
Total revenue	62,218	62,236	124,938	123,326
Core Products
Disaggregation of Revenue [Line Items]
Total revenue	44,844	43,738	93,730	91,576
Sample Repository Solutions
Disaggregation of Revenue [Line Items]
Total revenue	29,293	27,305	59,412	54,921
B Medical Systems
Disaggregation of Revenue [Line Items]
Total revenue	$ 22,779	$ 15,122	$ 35,371	$ 56,944

Revenue from Contracts with C_4

Revenue from Contracts with Customers - Contract Balances (Details) - USD ($) $ in Thousands	6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Sep. 30, 2023
Accounts Receivable, after Allowance for Credit Loss, Current [Abstract]
Accounts receivable, net	$ 154,668		$ 156,535
Contract with Customer, Asset, after Allowance for Credit Loss, Current [Abstract]
Contract assets	33,300		24,200
Contract with Customer, Liability [Abstract]
Contract liabilities	38,300		$ 34,600
Revenue recognized	$ 20,100	$ 22,400

Revenue from Contracts with C_5

Revenue from Contracts with Customers - Remaining Performance Obligations (Details) $ in Thousands	Mar. 31, 2024 USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	$ 122,098
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	$ 94,719
Unsatisfied performance obligation, period	12 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	$ 27,379
Unsatisfied performance obligation, period

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 5,602	$ 3,990	$ 8,804	$ 6,096
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	5,284	3,634	8,134	5,393
Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 318	$ 356	$ 670	$ 703

Stock-Based Compensation - Rest

Stock-Based Compensation - Restricted Stock Unit Activity - Tabular Disclosure (Details) - Restricted Stock Units (RSUs) - $ / shares	6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Outstanding at beginning of period (in shares)	718,954
Restricted stocks granted (in shares)	608,706	572,111
Vested (in shares)	(174,868)
Forfeited (in shares)	(298,806)
Outstanding at end of period (in shares)	853,986
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]
Outstanding at beginning of period (in dollars per share)	$ 67.40
Granted (in dollars per share)	55.69
Vested (in dollars per share)	68.95
Forfeited (in dollars per share)	63.75
Outstanding at end of period (in dollars per share)	$ 60.01

Stock-Based Compensation - Re_2

Stock-Based Compensation - Restricted Stock Unit Activity - Additional Information (Details) - Restricted Stock Units (RSUs) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of restricted stock awards vested	$ 2	$ 2.6	$ 9.8	$ 9.6
Restricted stocks granted (in shares)			608,706	572,111

Stock-Based Compensation - Re_3

Stock-Based Compensation - Restricted Stock Unit Activity - Unrecognized Compensation Cost (Details) - Restricted Stock Units (RSUs) $ in Millions	6 Months Ended
	Mar. 31, 2024 USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 27.2
Unrecognized compensation cost, estimated weighted average amortization period	1 year 10 months 24 days

Stock-Based Compensation - Re_4

Stock-Based Compensation - Restricted Stock Units Granted (Details) - shares	6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stocks granted (in shares)	608,706	572,111
Restricted Stock, Time Based Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stocks granted (in shares)	220,174	356,410
Restricted Stock, Performance Based Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stocks granted (in shares)	388,532	215,701

Stock-Based Compensation - Time

Stock-Based Compensation - Time-Based Restricted Stock Unit Grants (Details) - Restricted Stock, Time Based Shares	6 Months Ended
	Mar. 31, 2024
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)	3 years
Award vesting percentage (as a percent)	33.33%

Stock-Based Compensation - Perf

Stock-Based Compensation - Performance-Based Restricted Stock Unit Grants (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023	Sep. 30, 2023	Oct. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 5,602	$ 3,990	$ 8,804	$ 6,096
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	27,200		27,200
Stock-based compensation expense	5,284	$ 3,634	$ 8,134	$ 5,393
Restricted Stock, Performance Based Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance-based awards granted, percentage (as a percent)			200%		200%
Performance-based awards granted, percentage, maximum threshold met (as a percent)			100%		100%
Performance goal measurement period (in years)			3 years
Restricted Stock, Performance Based Shares, Modified Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost						$ 5,500
Stock-based compensation expense	$ 500		$ 700

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Sep. 30, 2023
Assets, Fair Value Disclosure [Abstract]
Available-for-sale securities	$ 611,238	$ 450,211
Derivative Asset, Statement of Financial Position	Prepaid expenses and other current assets	Prepaid expenses and other current assets
Fair Value, Recurring
Assets, Fair Value Disclosure [Abstract]
Available-for-sale securities	$ 611,238	$ 450,211
Foreign exchange contracts	217	44
Net investment hedge	350	13,036
Total Assets	807,202	989,243
Liabilities, Fair Value Disclosure [Abstract]
Foreign exchange contracts	141	421
Total Liabilities	141	421
Fair Value, Recurring | Cash Equivalents
Assets, Fair Value Disclosure [Abstract]
Cash equivalents	195,397	525,952
Fair Value, Recurring | Fair Value, Inputs, Level 1
Assets, Fair Value Disclosure [Abstract]
Available-for-sale securities	225,926	85,949
Total Assets	406,681	611,901
Fair Value, Recurring | Fair Value, Inputs, Level 1 | Cash Equivalents
Assets, Fair Value Disclosure [Abstract]
Cash equivalents	180,755	525,952
Fair Value, Recurring | Fair Value, Inputs, Level 2
Assets, Fair Value Disclosure [Abstract]
Available-for-sale securities	385,312	364,262
Foreign exchange contracts	217	44
Net investment hedge	350	13,036
Total Assets	400,521	377,342
Liabilities, Fair Value Disclosure [Abstract]
Foreign exchange contracts	141	421
Total Liabilities	141	$ 421
Fair Value, Recurring | Fair Value, Inputs, Level 2 | Cash Equivalents
Assets, Fair Value Disclosure [Abstract]
Cash equivalents	$ 14,642

Income Taxes - Income Tax Expen

Income Taxes - Income Tax Expense (Benefit) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Income Tax Expense (Benefit), Continuing Operations [Abstract]
Income tax expense (benefit)	$ (260)	$ (3,260)	$ (450)	$ (7,900)
Income tax expense valuation allowance recorded against deferred tax assets in a foreign subsidiary	1,700
Income tax expense for tax deductions that are lower than the associated book compensation expense	500
Income tax expense related to a valuation allowance on beginning of year deferred tax assets	700
Income tax expense related to a valuation allowance recorded against the current year deferred tax assets	$ 5,700		$ 8,300
Deferred tax benefit resulting from the extension of a tax incentive in China				1,400
Pre-tax income not subject to income taxes				$ 17,100

Income Taxes - Deferred Tax Ass

Income Taxes - Deferred Tax Assets Valuation Allowance (Details) $ in Millions	Mar. 31, 2024 USD ($)
State and Local Jurisdiction
Valuation Allowance [Line Items]
Deferred tax assets, valuation allowance	$ 0.7

Income Taxes - Deferred Tax A_2

Income Taxes - Deferred Tax Assets, Net (Details) $ in Millions	3 Months Ended	6 Months Ended
	Mar. 31, 2024 USD ($)	Mar. 31, 2024 USD ($)
Deferred Tax Assets, Net [Abstract]
Foreign earnings repatriated	$ 455
Income tax benefits, net, foreign earnings repatriated	3.2
Deferred tax assets, net, benefit, deductible foreign exchange losses on repatriation measured at foreign exchange rate	5.2	$ 5.2
Deferred tax liabilities, net, state income taxes, net of domestic benefit	$ 2	2
Deferred tax assets, net, increase (decrease), amount, changes in foreign exchange rates		$ (2.9)

Net Loss per Share (Details)

Net Loss per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]
Loss from continuing operations	$ (136,880)	$ (1,991)	$ (152,604)	$ (13,226)
Loss from discontinued operations, net of tax		(2,936)		(2,936)
Net Income (Loss)	(136,880)	(4,927)	(152,604)	(16,162)
Net loss - basic	(136,880)	(4,927)	(152,604)	(16,162)
Net loss - diluted	$ (136,880)	$ (4,927)	$ (152,604)	$ (16,162)
Weighted Average Number of Shares Outstanding, Diluted [Abstract]
Weighted average common shares outstanding used in computing basic loss per share (in shares)	55,440	69,111	56,078	70,858
Weighted average common shares outstanding used in computing diluted loss per share (in shares)	55,440	69,111	56,078	70,858
Earnings Per Share, Basic [Abstract]
Loss from continuing operations (in dollars per share)	$ (2.47)	$ (0.03)	$ (2.72)	$ (0.19)
Loss from discontinued operations, net of tax (in dollars per share)		(0.04)		(0.04)
Basic net loss per share (in dollars per share)	(2.47)	(0.07)	(2.72)	(0.23)
Earnings Per Share, Diluted [Abstract]
Loss from continuing operations (in dollars per share)	(2.47)	(0.03)	(2.72)	(0.19)
Loss from discontinued operations, net of tax (in dollars per share)		(0.04)		(0.04)
Diluted net loss per share (in dollars per share)	$ (2.47)	$ (0.07)	$ (2.72)	$ (0.23)

Segment and Geographic Inform_3

Segment and Geographic Information - General Information (Details) - segment	3 Months Ended		6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]
Number of reportable segments	3	3	3	3

Segment and Geographic Inform_4

Segment and Geographic Information - Reconciliation of Reportable Segment Operating Income (Loss) to Corresponding Consolidated Amounts (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Segment Reporting Information [Line Items]
Total revenue	$ 159,134	$ 148,401	$ 313,451	$ 326,767
Amortization of other intangible assets	13,000	12,400	25,500	24,000
Purchase accounting impact on inventory		2,912		5,781
Transformation costs	4,446	10	4,487	(55)
Restructuring charges	7,344	1,499	8,464	2,961
Impairment of goodwill and intangible assets	115,975		115,975
Provisions			3,231	2,961
Contingent consideration - fair value adjustments		(17,145)		(17,145)
Merger and acquisition costs and costs related to share repurchase	426	19	4,747	11,857
Total operating loss	(146,955)	(12,977)	(173,632)	(40,662)
Interest income, net	9,565	10,394	19,646	21,059
Other income (expense), net	250	(2,668)	932	(1,523)
Loss before income taxes	(137,140)	(5,251)	(153,054)	(21,126)
Completed Technology
Segment Reporting Information [Line Items]
Amortization of other intangible assets	6,373	4,901	12,000	9,070
Intangible Assets Excluding Completed Technology
Segment Reporting Information [Line Items]
Amortization of other intangible assets	6,654	7,509	13,516	14,882
Sample Management Solutions
Segment Reporting Information [Line Items]
Total revenue	74,137	71,043	153,142	146,498
Multiomics
Segment Reporting Information [Line Items]
Total revenue	62,218	62,236	124,938	123,325
B Medical Systems
Segment Reporting Information [Line Items]
Total revenue	22,779	15,122	35,371	56,944
Operating Segments
Segment Reporting Information [Line Items]
Total operating loss	(5,686)	(13,254)	(14,402)	(13,213)
Operating Segments | Revision of Prior Period, Adjustment
Segment Reporting Information [Line Items]
Total operating loss		8,000		16,500
Operating Segments | Sample Management Solutions
Segment Reporting Information [Line Items]
Total operating loss	(1,567)	(6,076)	(2,423)	(9,074)
Operating Segments | Multiomics
Segment Reporting Information [Line Items]
Total operating loss	(2,966)	(3,810)	(6,417)	(7,075)
Operating Segments | B Medical Systems
Segment Reporting Information [Line Items]
Total operating loss	(1,153)	(3,367)	(5,562)	2,936
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Other unallocated corporate expense	$ 51	$ 18	$ 41	$ 98

Segment and Geographic Inform_5

Segment and Geographic Information - Financial Information for Business Segments - Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Sep. 30, 2023
Segment Reporting Information [Line Items]
Total assets	$ 2,563,497	$ 2,885,720
Operating Segments
Segment Reporting Information [Line Items]
Total assets	1,557,205	1,721,785
Operating Segments | Sample Management Solutions
Segment Reporting Information [Line Items]
Total assets	845,641	675,708
Operating Segments | Multiomics
Segment Reporting Information [Line Items]
Total assets	462,684	534,437
Operating Segments | B Medical Systems
Segment Reporting Information [Line Items]
Total assets	$ 248,880	$ 511,640

Segment and Geographic Inform_6

Segment and Geographic Information - Reconciliation of Reportable Segment Assets to Corresponding Consolidated Amounts (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Sep. 30, 2023
Segment Reporting Information [Line Items]
Cash and cash equivalents, restricted cash, and marketable securities	$ 975,358	$ 1,134,256
Deferred tax asset	925	571
Other assets	30,009	29,108
Assets	2,563,497	2,885,720
Operating Segments
Segment Reporting Information [Line Items]
Assets	$ 1,557,205	$ 1,721,785

Segment and Geographic Inform_7

Segment and Geographic Information - Net Revenues Based upon Source of Order by Geographic Area - Tabular Disclosure (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	$ 159,134	$ 148,401	$ 313,451	$ 326,767
North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	88,398	86,572	178,990	174,321
Rest of Europe
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	23,850	21,432	48,682	60,854
United Kingdom
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	5,641	5,789	11,340	11,202
Africa
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	18,942	8,627	26,453	25,837
China
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	13,646	11,979	28,544	25,387
Asia / Pacific / Other
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	$ 8,657	$ 14,002	$ 19,442	$ 29,166

Segment and Geographic Inform_8

Segment and Geographic Information - Net Revenues Based upon Source of Order by Geographic Area - Additional Information (Details) - country	3 Months Ended	6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Top Individual Customer
Concentration Risk [Line Items]
Number of countries in which entity operates	14	17
Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Top Individual Customer | Minimum
Concentration Risk [Line Items]
Concentration risk (as a percent)	10%	10%

Commitments and Contingencies -

Commitments and Contingencies - Contingencies (Details) - Edwards Vacuum LLC, Indemnification, Definitive Agreement, Third-party Warranty Claim - USD ($) $ in Millions	1 Months Ended		3 Months Ended
	Apr. 30, 2023	Jan. 31, 2023	Jun. 30, 2023	Mar. 31, 2024	Mar. 31, 2023
Loss Contingency, Information about Litigation Matters [Abstract]
Loss contingency, damages sought, value		$ 1
Loss Contingency Accrual, Disclosures [Abstract]
Loss contingency accrual					$ 2.5
Settled Litigation
Loss Contingency Accrual, Disclosures [Abstract]
Loss contingency accrual				$ 1.7
Loss contingency payment	$ 0.8		$ 0.8

Commitments and Contingencies_2

Commitments and Contingencies - Tariff Matter (Details) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Mar. 31, 2024	Sep. 30, 2022
Tariffs
Loss Contingency Accrual, Disclosures [Abstract]
Loss contingency payment	$ 3.2	$ 5.9

Commitments and Contingencies_3

Commitments and Contingencies - Purchase Commitments (Details) $ in Millions	Mar. 31, 2024 USD ($)
Non-cancelable Commitments
Other Commitments [Line Items]
Other commitment	$ 52
Non-cancellable Contracts and Purchase Orders for Inventory
Other Commitments [Line Items]
Other commitment	47.9
Non-cancelable Information Technology-related Commitments
Other Commitments [Line Items]
Other commitment	$ 4.1

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (136,880)	$ (4,927)	$ (152,604)	$ (16,162)

Insider Trading Arrangements

Insider Trading Arrangements - Stephen S. Schwartz	3 Months Ended
	Mar. 31, 2024 shares
Trading Arrangements, by Individual
Material Terms of Trading Arrangement	Item 5. Other Information Rule 10b5-1 Trading Arrangements During the three months ended March 31, 2024, the On March 8, 2024, Stephen S. Schwartz, our President and CEO, adopted a Rule 10b5-1 trading arrangement (as defined in Item 408(a) of Regulation S-K) for the period commencing ninety-one days from such date and ending on June 6, 2025 for the sale of up to 89,344 shares of common stock of the Company.
Name	Stephen S. Schwartz
Title	President and CEO
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	March 8, 2024
Arrangement Duration	91 days
Aggregate Available	89,344
Trd Arr Expiration Date	Jun. 06, 2025